<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        131-9-16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TEGRETOL CR 200MG SCORED TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CARBAMAZEPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        40.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AF01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tegretol Prolonged Release Tablets are specially formulated to release the active ingredient gradually.&nbsp;</p><p>Carbamazepine, the active ingredient, can affect the body in several different ways.&nbsp; It is an anti-convulsant medicine (prevents fits), it can also modify some types of pain and can control mood disorders.&nbsp;</p><p>&nbsp;</p><p>Tegretol Prolonged Release Tablets are used</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To treat certain types of seizures (epilepsy).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To treat certain psychiatric conditions (such as a disorder known as mania episodes of bipolar mood disorders and a certain type of depression).</p><p>&Oslash;&nbsp; It must not be used for common aches or pains.</p><p>&Oslash;&nbsp; Epilepsy is a disorder characterized by two or more seizures (fits). Seizures occur when messages from the brain to the muscles are not properly passed on by the nerve pathways in the body.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tegretol helps to control the passing-on of these messages.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tegretol also regulates nerve functions for the other diseases mentioned above.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take Tegretol Prolonged Release</strong><strong> </strong><strong>Tablets</strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong>Some people MUST NOT take Tegretol.&nbsp; Talk to your doctor if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you think you may be hypersensitive (allergic) to carbamazepine or similar drugs such as oxcarbazepine (Trileptal), or to any of a related group of drugs known as tricyclic antidepressants (such as amitriptyline or imipramine).&nbsp; If you are allergic to carbamazepine there is a one in four (25%) chance that you could also have an allergic reaction to oxcarbazepine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you think you may be allergic to any of the other ingredients of Tegretol Prolonged Release Tablets (these are listed at the end of the leaflet).&nbsp; Signs of a hypersensitivity reaction include swelling of the face or mouth (angioedema), breathing problems, runny nose, skin rash, blistering or peeling.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have any heart problems,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had problems with your bone marrow,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a blood disorder called porphyria,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have taken drugs called monoamine oxidase inhibitors (MAOIs), used to treat depression, within the last 14 days.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of these apply to you, do not take Tegretol and tell your doctor.</p><p>&nbsp;</p><p>A small number of people being treated with anti-epileptics such as carbamazepine have had thoughts of harming or killing themselves.&nbsp; If at any time you have these thoughts, immediately contact your doctor.</p><p>&nbsp;</p><p>If an allergic reaction happens, such as swelling of lips, eyelids, face, throat, mouth, or sudden breathing problems, fever with lymph nodes swelling, rash or skin blistering, tell your doctor immediately or go to the emergency department at your nearest hospital (see &ldquo;Possible side effects&rdquo;).</p><p>&nbsp;</p><p>Serious skin rashes (Stevens- Johnson syndrome, toxic epidermal necrolysis) have been reported with the use of carbamazepine. Frequently, the rash can involve ulcers of the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). These serious skin rashes are often preceded by influenza-like symptoms fever, headache, body ache (flu-like symptoms). The rash may progress to widespread blistering and peeling of the skin. The highest risk for occurrence of serious skin reactions is within the first months of treatment.</p><p>&nbsp;</p><p>These serious skin reactions can be more common in people from some Asian countries. The risk of these reactions in patients of Han Chinese or Thai origin may be predicted by testing a blood sample of these patients. Your doctor should be able to advise if a blood test is necessary before taking carbamazepine.</p><p>&nbsp;</p><p>If you develop a rash or these skin symptoms, stop taking carbamazepine and contact your doctor immediately.</p><p>&nbsp;</p><p>If you experience dizziness, drowsiness, decrease in blood pressure, confusion, due to Tegretol treatment, this may lead to falls.</p><p>&nbsp;</p><p><strong>b. Take special care with Tegretol Prolonged Release</strong><strong> </strong><strong>Tablets</strong></p><p>&nbsp;</p><p><strong>You should also ask yourself these questions before taking Tegretol Prolonged Release Tablets.&nbsp; If the answer to any of these questions is YES, discuss your treatment with your doctor or pharmacist because Tegretol Prolonged Release Tablets might not be the right medicine for you.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are you pregnant or planning to become pregnant?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are you breastfeeding?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do you suffer from the sort of epilepsy where you get mixed seizures which include absences?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do you have any mental illness?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are you allergic to an epilepsy medicine called phenytoin, primidone or phenobarbital?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do you have liver problems?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do you have kidney problems associated with low sodium blood level or do you have kidney problems and you are taking certain medicines that lower sodium blood levels (diuretics such as hydrochlorothiazide, furosemide)?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are you elderly?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do you have any eye problems such as glaucoma (increased pressure in the eye) or do you have difficulty or pain when passing &nbsp;urine?</p><p><strong>&nbsp;</strong></p><p><strong>c. Taking other medicines, herbal or dietary supplements</strong></p><p><strong>&nbsp;</strong></p><p><strong>Are you taking other medicines?</strong></p><p>Because of the way that Tegretol works, it can affect, and be affected by, lots of other things that you might be eating or medicines that you are taking.&nbsp; It is very important to make sure that your doctor knows all about what else you are taking, including anything that you have bought from a chemist or health food shop.&nbsp; It may be necessary to change the dose of some medicines, or stop taking something altogether.</p><p>&nbsp;</p><p><u>Tell the doctor if you are taking:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hormone contraceptives, e.g. pills, patches, injections or implants.&nbsp; Tegretol affects the way the contraceptive works in your body, and you may get breakthrough bleeding or spotting.&nbsp; It may also make the contraceptive less effective and there will be a risk of getting pregnant.&nbsp; Your doctor will be able to advise you about this, and you should think about using other effective contraceptives.&nbsp;&nbsp;If you are a female of childbearing age you should use an effective method of contraception throughout your treatment and for a period of 28 days, after discontinuation of treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hormone Replacement Therapy (HRT). &nbsp;Tegretol can make HRT less effective.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any medicines for depression or anxiety.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroids (&lsquo;steroids&rsquo;).&nbsp; You might be taking these for inflammatory conditions such as asthma, inflammatory bowel disease, muscle and joint pains.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anticoagulants to stop your blood clotting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antibiotics to treat infections including skin infections and TB (e.g. ciprofloxacillin).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antifungals to treat fungal infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painkillers containing paracetamol, dextropropoxyphene, tramadol, methadone or buprenorphine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines to treat epilepsy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for high blood pressure or heart problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antihistamines (medicines to treat allergy such as hayfever, itch, etc).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diuretics (water tablets).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cimetidine or omeprazole (medicines to treat gastric ulcers).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Isotretinoin (a medicine for the treatment of acne).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metoclopramide or aprepitant (anti-sickness medications).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acetazolamide (a medicine to treat glaucoma - increased pressure in the eye).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Danazol or gestrinone (treatments for endometriosis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Theophylline or aminophylline (used in the treatment of asthma).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ciclosporin, tacrolimus or sirolimus (immunosuppressants, used after transplant operations, but also sometimes in the treatment of arthritis or psoriasis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drugs to treat schizophrenia (e.g. paliperidone, aripiprazole).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cancer drugs (e.g. temsirolimus, cyclophasphamide, lapatinib).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The anti-malarial drug, mefloquine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drugs to treat HIV.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Levothyroxine (used to treat hypothyroidism).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tadalafil (used to treat impotence).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Albendazole (used to treat worms).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bupropion (used to help stop smoking).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A herbal remedy called St John&rsquo;s Wort or Hypericum.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drugs or supplements containing Vitamin B (nicotinamide).</p><p><strong>d. Pregnancy and breastfeeding</strong></p><p><strong>Pregnancy</strong></p><p>If you are a woman who is able to have a baby and are not planning a pregnancy, you should use effective contraception during treatment with Tegretol. Tegretol may affect how hormonal contraceptives, such as the contraceptive (birth control) pill, work and make them less effective at preventing pregnancy. Talk to your doctor, who will discuss with you the most suitable type of contraception to use while you are taking Tegretol. If treatment with Tegretol is discontinued, you should continue using effective contraception for at least two more weeks following discontinuation.</p><p>&nbsp;</p><p>If you are pregnant, or think you may be pregnant, you must tell your doctor straight away and discuss possible risks the epilepsy medicine you are taking might pose to your unborn baby.</p><p>&nbsp;</p><p>If you are planning to become pregnant you should discuss your epilepsy treatment with your doctor as early as possible before you become pregnant.</p><p>&nbsp;</p><p>You should not stop your treatment without discussing this with your doctor. Suddenly stopping may lead to breakthrough seizures which may harm you and your unborn baby. It is important that your epilepsy remains well controlled.</p><p>&nbsp;</p><p>Taking carbamazepine during pregnancy increases the chance that the baby may have a physical birth abnormality (major congenital malformations). Studies with women treated with carbamazepine for epilepsy have shown that on average 4-5 babies in every 100 will have serious physical birth abnormalities. This is compared with 2 to 3 babies in every 100 born to women who do not have epilepsy.</p><p>&nbsp;</p><p>These abnormalities can develop early in pregnancy, even before you know you are pregnant. The most common types of major congenital malformations reported for carbamazepine include spina bifida (where the bones of the spine are not properly developed); facial and skull malformations including cleft lip/palate;</p><p>skeletal, heart, urinary tract and sexual organ malformations.</p><p>&nbsp;</p><p>Studies have found that the risk of physical birth abnormalities increases with increasing doses of carbamazepine. Therefore, it is important that where possible you are prescribed the lowest dose to control your epilepsy.</p><p>&nbsp;</p><p>Ask your doctor about taking folic acid when trying for a baby and during pregnancy. Folic acid may lower the general risk of serious physical birth abnormalities that exists with all pregnancies.</p><p>&nbsp;</p><p>Taking more than one epilepsy medicine at the same time may also increase the risk of physical birth abnormalities. This means that where possible, your doctor should consider using one epilepsy medicine to control your epilepsy.</p><p>&nbsp;</p><p>Problems with neurodevelopment (development of the brain) cannot be ruled out in children born to women with epilepsy treated with carbamazepine alone or in combination with other antiepileptic drugs during pregnancy.</p><p>&nbsp;</p><p>If you take Tegretol during pregnancy, your baby is also at risk for bleeding problems right after birth. Your doctor may give you and your baby a medicine to prevent this.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Breastfeeding</strong></p><p>Mothers taking Tegretol Prolonged Release Tablets can breastfeed their babies, but you must tell the doctor as soon as possible if you think that the baby is suffering side effects such as excessive sleepiness, skin reaction or yellow skin and eyes, dark urine or pale stools.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>You should use an effective method of contraception throughout your treatment with Tegretol and for a period of 28 days, after discontinuation of treatment. Irregularity of the menstrual period may occur in women taking hormonal contraceptives (birth control medicines) and Tegretol. The hormonal contraceptive may become less effective and you should consider using a different or additional non-hormonal contraceptive method. Ask your doctor about effective contraception.</p><p>&nbsp;</p><p><strong>e. Driving and using machines</strong></p><p>&nbsp;</p><p><strong>Will there be any problems with driving or using machinery?</strong></p><p>Tegretol Prolonged Release Tablets can make you feel dizzy or drowsy, or may cause blurred vision, double vision, or you may have a lack of muscular coordination, especially at the start of treatment or when the dose is changed.&nbsp; If you are affected in this way, or if your eyesight is affected, you should not drive or operate machinery.</p><p>&nbsp;</p><p>Tegretol Prolonged Release Tablets contain macrogolglycerol hydroxystearate:</p><p>Macrogolglycerol hydroxystearate may cause stomach upset and diarrhoea.</p><p>&nbsp;</p><p>Information about sodium content:</p><p>This medicine contains less than 1mmol sodium (23mg) per tablet, that is to say essentially &lsquo;sodium free&rsquo;.</p><p>&nbsp;</p><p>Other special warnings</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drinking alcohol may affect you more than usual.&nbsp; Discuss whether you should stop drinking with your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eating grapefruit, or drinking grapefruit juice, may increase your chance of experiencing side effects.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may want you to have a number of blood tests before you start taking Tegretol and from time to time during your treatment.&nbsp; This is quite usual and nothing to worry about.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tegretol is an anti-epileptic medical product. Treatment with Tegretol should be initiated and supervised by a physician experienced in the use of anti-epileptic medicinal products. Follow instructions for disposal in section 6 (How to store Tegretol prolonged release tablet).</p><p><strong>&nbsp;</strong></p><p><strong>The doctor will tell you how many Tegretol Prolonged Release Tablets to take and when to take them.&nbsp; Always follow his/her instructions carefully.&nbsp; The dose will be on the pharmacist&rsquo;s label.&nbsp; Check the label carefully.&nbsp; It is important to take the tablets at the right times.&nbsp; If you are not sure, ask your doctor or pharmacist.&nbsp; Keep taking your tablets for as long as you have been told, unless you have any problems.&nbsp; In that case, check with your doctor.</strong></p><p>Your doctor will usually start Tegretol at a fairly low dose which can then be increased to suit you individually.&nbsp; The dose needed varies between patients.&nbsp; You can take Tegretol Prolonged Release Tablets during, after or between meals.&nbsp; <strong>Swallow the tablets with a drink.&nbsp; Do not chew them.</strong>&nbsp; You are usually told to take a dose two or three times a day.&nbsp; If necessary you may break the tablets in half along the scored line.</p><p>To treat epilepsy the usual doses are:</p><p><strong>Adults:</strong> 800-1,200 mg a day, although higher doses may be necessary.&nbsp; If you are elderly you might require a lower dose.</p><p>&nbsp;</p><p><strong>Children: </strong></p><p>Aged 5-10 years: 400-600 mg a day</p><p>Aged 10-15 years: 600-1,000 mg a day.</p><p>&nbsp;</p><p>Tegretol Prolonged Release Tablets are not recommended for children under 5.</p><p>&nbsp;</p><p>To treat trigeminal neuralgia the usual dose is: 600-800 mg a day. The maximum dose is 1200mg a day. If you are elderly you might require a lower dose.&nbsp;</p><p>&nbsp;</p><p>To treat mood swings the usual dose is: 400-600 mg a day</p><p><strong>&nbsp;</strong></p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you take more Tegretol Prolonged Release</strong><strong> </strong><strong>Tablets than you should</strong></p><p>If you accidentally take too many Tegretol CR Tablets, tell your doctor or your nearest hospital casualty department.&nbsp; Take your medicine pack with you so that people can see what you have taken.</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp; </strong><strong>If you forget to take Tegretol Prolonged Release</strong><strong> </strong><strong>Tablets than you should</strong></p><p>If you forget to take a dose, take one as soon as you remember.&nbsp; If it is nearly time for your next dose, though, just take the next dose and forget about the one you missed.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tegretol Tablets do not usually cause problems, but like all medicines, they can sometimes cause side effects.</p><p>&nbsp;</p><p><strong><u>Some side effects can be serious</u></strong></p><p><strong>Stop taking Tegretol </strong><strong>CR </strong><strong>Tablets and tell your doctor straight away if you notice:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious skin reactions such as rash, red skin, blistering of the lips, eyes or mouth, or skin peeling accompanied by fever.&nbsp; These reactions may be more frequent in patients of Chinese or Thai origin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mouth ulcers or unexplained bruising or bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore throat or high temperature, or both</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellowing of your skin or the whites of your eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swollen ankles, feet or lower legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any signs of nervous illness or confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in your joints and muscles, a rash across the bridge of the nose and cheeks and problems with breathing (these may be the signs of a rare reaction known as lupus erythematosus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, skin rash, joint pain, and abnormalities in blood and liver function tests (these may be the signs of a multi-organ sensitivity disorder)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bronchospasm with wheezing and coughing, difficulty in breathing, feeling faint, rash, itching or facial swelling (these may be the signs of a severe allergic reaction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in the area near the stomach</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You experience a fall due to dizziness, drowsiness, decrease in blood pressure, confusion.</p><p>&nbsp;</p><p><strong><u>The side effects listed below have also been reported.</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong>Very Common (may </strong><strong>affect More than 1 in 10 people):</strong></p><p>Leucopenia (a reduced number of the cells which fight infection making it easier to catch infections); dizziness and tiredness; feeling unsteady or finding it difficult to control movements; feeling or being sick; changes in liver enzyme levels (usually without any symptoms); skin reactions which may be severe.</p><p>&nbsp;</p><p><strong>Common (may affect Up to 1 in 10 people):</strong></p><p>Changes in the blood including an increased tendency to bruise or bleed; fluid retention and swelling; weight increase; low sodium in the blood which might result in confusion; headache; double or blurred vision; dry mouth.</p><p>&nbsp;</p><p><strong>Uncommon (May affect Up to 1 in 100 people):</strong></p><p>Abnormal involuntary movements including tremor or tics; abnormal eye movements; diarrhoea; constipation.</p><p>&nbsp;</p><p><strong>Rare (May affect Up to 1 in 1,000 people):</strong></p><p>Disease of the lymph glands; folic acid deficiency; a generalised allergic reaction including rash, joint pain, fever, problems with the kidneys and other organs; hallucinations; depression; loss of appetite; restlessness; aggression; agitation; confusion; speech disorders; numbness or tingling in the hands and feet; muscle weakness; high blood pressure (which may make you feel dizzy, with a flushed face, headache, fatigue and nervousness); low blood pressure (the symptoms of which are feeling faint, light headed, dizzy, confused, having blurred vision); changes to heart beat; stomach pain; liver problems including jaundice; symptoms of lupus.</p><p>&nbsp;</p><p><strong>Very Rare (may affect Up to 1 in 10,000 people):</strong></p><p>Changes to the composition of the blood including anaemia; porphyria; meningitis; swelling of the breasts and discharge of milk which may occur in both male and females; abnormal thyroid function tests; osteomalacia (which may be noticed as pain on walking and bowing of the long bones in the legs); osteoporosis; increased blood fat levels; taste disturbances; conjunctivitis; glaucoma; cataracts; hearing disorders; heart and circulatory problems including deep vein thrombosis (DVT), the symptoms of which could include tenderness, pain, swelling, warmth, skin discoloration and prominent superficial veins; lung or breathing problems; severe skin reactions including Stevens-Johnson syndrome (These reactions may be more frequent in patients of Chinese or Thai origin); sore mouth or tongue; liver failure; increased sensitivity of the skin to sunlight; alterations in skin pigmentation; acne; excessive sweating; hair loss; increased hair growth on the body and face; muscle pain or spasm; sexual difficulties which may include reduced male fertility, loss of libido or impotence; kidney failure; blood spots in the urine; increased or decreased desire to pass urine or difficulty in passing urine.</p><p>&nbsp;</p><p><strong>Not Known (frequency cannot be estimated from the available data):</strong><strong> </strong></p><p>The following have also been reported, but the frequency cannot be estimated from the available information:</p><p>Severe skin reactions, accompanied by feeling unwell and changes in blood results. Diarrhoea, abdominal pain, and fever (signs of inflammation of the colon), reactivation of herpes virus infection (can be serious when immune system is depressed), complete loss of nails, fracture, decrease in the measure of the bone density, drowsiness, memory loss, purple or reddish-purple bumps that may be itchy.</p><p>&nbsp;</p><p><strong>Do not be alarmed by this list.&nbsp; Most people take Tegretol Prolonged Release Tablets without any problems.</strong></p><p>&nbsp;</p><p><strong>If any of the symptoms become troublesome, or if you notice anything else not mentioned here, please go and see your doctor.&nbsp; He/she may want to give you a different medicine.</strong><strong> </strong></p><p>&nbsp;</p><p>There have been reports of bone disorders including osteopenia and osteoporosis (thinning of the bone) and fractures. Check with your doctor or pharmacist if you are on long-term antiepileptic medication, have a history of osteoporosis, or take steroids.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>&nbsp; &nbsp;Do not store above 30&deg;C.</li><li>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from moisture.</li><li>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</li><li>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take Tegretol Tablets after the expiry date which is printed on the outside of the pack.</li></ul><p><u>Handling:</u><u> </u></p><p>Tegretol is an anti-epileptic medical product. In healthcare settings, use designated area for medication storage and restrict access to only authorized personnel.</p><p><u>Disposal:</u><u> </u></p><ul><li>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any unused medicinal product or waste material should be disposed in accordance with local&nbsp; requirements. Wash hands thoroughly with water after disposal of any unused medicinal product or waste material.</li><li>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor tells you to stop taking the tablets, please take any unused tablets back to your pharmacist to be destroyed.&nbsp;</li><li>Do not throw them away with your normal household water or waste.&nbsp; This will help to protect the environment.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp; The tablets come in two strengths containing either 200 or 400 mg of the active ingredient carbamazepine.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp; The tablets also contain the inactive ingredients colloidal silicon dioxide, ethylcellulose aqueous dispersion, microcrystalline cellulose, ethyl acrylate/methyl methacrylate copolymer, magnesium stearate, croscarmellose sodium type A, talc, hydroxypropylmethylcellulose, glyceryl polyoxyethylene glycol stearate, red and yellow iron oxide (E172) and titanium dioxide (E171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tegretol Prolonged Release 200 mg Tablets are oval, beige-orange tablets with a score on each side.  One side bears the imprint “HC”, the other “CG”.
They come in blister packs of 50.

Tegretol Prolonged Release 400 mg are oval, brownish-orange tablets with a score on each side.  One side bears the imprint “ENE/ENE”, the other “CG/CG”.

They come in blister packs of 30 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2024
e. To report any side effect(s):
•	Saudi Arabia

The National Pharmacovigilance Center (NPC):
o SFDA call center: 19999
o E-mail: npc.drug@sfda.gov.sa
o Website: https://ade.sfda.gov.sa 

Patient Safety Department Novartis Consulting AG - Saudi Arabia:
o Toll Free Number: 8001240078
o Phone: +966112658100 
o Fax: +966112658107
o Email: adverse.events@novartis.com  

•    Other GCC States:
-  Please contact the relevant competent authority.

f. To report any complaint(s): complaints.ksa@novartis.com 

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>أقراص تجريتول ممتدة المفعول مصنعّة خصيصًا لانتشار المادة الفعالة في الجسم بشكل تدريجي.</p><p>كاربامازيبين هي المادة الفعالة التي يمكن أن تؤثر على الجسم بطرق مختلفة.&nbsp; ينتمي تجريتول إلى مجموعة من الأدوية تُسمَّى مضادات الصرع (أدوية لعلاج التشنجات)، يمكن أيضًا معالجة بعض أنواع الألم والتحكم في اضطرابات المزاج.</p><p>&nbsp;</p><p><strong>أقراص تجريتول ممتدة المفعول تستخدم للتالي:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج أنواع معيَّنة من التشنجات (الصرع).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج بعض الأمراض النفسية (مثلاً اضطراب يُسمى نوبات الهوس في الاضطرابات المزاجية ثنائية القطب ونوع معيَّن من الاكتئاب).</p><p>&Oslash;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي استعماله لعلاج الأوجاع أو الآلام العادية.</p><p>&Oslash;&nbsp;&nbsp;&nbsp;&nbsp; الصرع هو اضطراب يتصف بحدوث اثنين أو أكثر من نوبات التشنج. تحدث نوبات التشنج عندما يختل مرور الإشارات من الدماغ إلى العضلات عبر المسارات العصبية في الجسم.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يساعد تجريتول في ضبط مرور هذه الإشارات.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يعمل تجريتول أيضاً على تنظيم وظائف الأعصاب في الأمراض الأخرى المذكورة عاليه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>موانع استعمال </strong><strong>أقراص </strong><strong>تجريتول ممتدة المفعول</strong></p><p><strong>بعض الأشخاص لا يجب عليهم أخذ تجريتول، أخبر طبيبك إذا كنت تعاني أحد الحالات التالية:</strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت تعتقد أن لديك أرجية (حساسية مفرطة) تجاه كاربامازيبين أو أي أدوية أخرى مشابهة مثل أوكسكاربازيبين (تريليبتال) أو لأي من الأدوية ذات الصلة بـمجموعة أدوية الاكتئاب ثلاثية الحلقات (مثل أميتريبتيلين أو إيميبرامين)، إذا كانت لديك حساسية مفرطة تجاه كاربامازيبين، فهناك احتمال بنسبة 1 من 4 تقريباً (25%) بأن تكون لديك أيضاً حساسية مفرطة تجاه أوكسكاربازيبين</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كانت تعتقد أن لديك أرجية (حساسية مفرطة) تجاه أي من المكونات الأخرى في تجريتول (المذكورة في نهاية هذه النشرة). علامات تفاعل فرط الحساسية تشمل تورم في الوجه أو الفم (وذمة وعائية) ، ومشاكل في التنفس ، سيلان في الأنف ، طفح جلدي، &nbsp;ظهور تقرحات أو تقشير.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي مشاكل في القلب.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي مشاكل في نخاع العظم.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;أذا كنت تعاني من أمراض الدم التي تدعى (بورفوريا)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى أيضاً أدوية تنتمي إلى مجموعة خاصة من مضادات الاكتئاب تُسمى مثبطات أحادي أمين أوكسيديز (MAOIs)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت أي من هذه الحالات تنطبق عليك، فلا تتناول تجريتول وأخبر طبيبك.</p><p>&nbsp;</p><p>عدد قليل من الأشخاص الذين يتعالجون بأدوية منع التشنجات مثل كاربامازيبين، كانت لديهم أفكار عن إيذاء أو قتل أنفسهم. في حال خطرت لك هذه الأفكار في أي وقت، فاتصل بطبيبك فورًا.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا حدث رد فعل تحسسي، مثل تورم الشفاه أو الجفون أو الوجه أو الحلق أو الفم أو مشاكل مفاجئة في التنفس، أو حمى مع تورم العقد الليمفاوية، أو طفح جلدي أو تقرحات جلدية، أخبر طبيبك على الفور أو قم بزيارة قسم الطوارئ في أقرب مستشفى لديك. (انظر قسم &quot;الأعراض الجانبية المحتملة&quot;).</p><p dir="RTL">&nbsp;</p><p>تم الإبلاغ عن طفح جلدي شديد (متلازمة ستيفنز جونسون ، تنخر البشرة السام) عند استخدام كاربامازيبين. في كثير من الأحيان ، يمكن أن يشتمل الطفح على قرحة في الفم والحلق والأنف والأعضاء التناسلية والتهاب الملتحمة (العيون الحمراء والمنتفخة). غالبًا ما تسبق هذه الطفح الجلدي الشديد أعراض تشبه الحمى لأعراض الإنفلونزا، الصداع وآلام الجسم (أعراض تشبه أعراض الأنفلونزا). قد يتطور الطفح الجلدي إلى ظهور تقرحات وتقشير على نطاق واسع. أعلى مراحل الخطر لحدوث ردات فعل جلدية شديدة هو خلال الأشهر الأولى من العلاج.</p><p>&nbsp;</p><p>ذاك الطفح الجلدي الشديد أكثر شيوعًا في المرضى من البلدان الآسيوية، إن مخاطرة حدوث تفاعلات جلدية شديدة في المرضى الذين يرجع أصلهم العرقي إلى الصينيين الهان أو إلى الأصل التايلاندي يمكن التنبؤ بها من خلال تحليل عينة دم لهؤلاء المرضى. سيحدد طبيبك ما إذا كان من الضروري إجراء تحليل دم قبل استعمال تجريتول.</p><p>&nbsp;</p><p>إذا انطبق عليك طفح جلدي، أو أي من تلك الأعراض الجلدية، فتوقف عن استعمال تجريتول وأخبر طبيبك فورًا.</p><p>&nbsp;</p><p>إذا كنت تعاني من الدوخة والنعاس وانخفاض ضغط الدم والارتباك بسبب علاج تجريتول، فقد يؤدي ذلك إلى السقوط.</p><p>&nbsp;</p><p><strong>ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الاحتياطات عند استعمال أقراص </strong><strong>تجريتول ممتدة المفعول</strong></p><p><strong>يجب عليك أيضا أن تسأل نفسك هذه الأسئلة قبل أخذ علاج تجريتول، إذا كانت الإجابة على أي من هذه الأسئلة هي نعم ، فناقش علاجك مع طبيبك أو الصيدلي لأن </strong><strong>تجريتول</strong><strong> قد لا يكون الدواء المناسب لك.</strong></p><p><strong>&nbsp;</strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل أنت حامل أو تنوين الحمل؟</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل أنت مرضع؟</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تعاني من نوع من الصرع حيث تصاب بنوبات مختلطة تشمل الغياب؟</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل ليك أي مرض عقلي؟</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل لديك حساسية من أدوية الصرع التي تسمى (فينيتوين، بريميدون، أو فينوباربيتال)؟</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تعاني من أمراض الكبد؟</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل لديك مشاكل في الكلى مصحوبة بانخفاض مستوى الصوديوم في الدم أو إذا كانت لديك مشاكل في الكلى وكنت تتلقى أيضاً أدوية معيَّنة تقلل مستوى الصوديوم في الدم (مدرات البول مثل هيدروكلوروثيازيد، فيوروسيميد).</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل أنت كبير في السن؟</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل لديك مشاكل في العين مثل جلوكوما (ارتفاع في ضغط العين) أو هل تعاني من صعوبة أو ألم عند التبول؟</p><p><strong>ج. </strong><strong>التداخلات الدوائية من أخذ تجريتول مع أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p>&nbsp;</p><p><strong>هل تستعمل أدوية أخرى؟</strong></p><p>نظرًا للطريقة التي يعمل بها عقار تجريتول ، فإنه يمكن أن يؤثر على الكثير من الأشياء الأخرى التي قد تتناولها أو الأدوية التي تتناولها ، ويتأثر بها. من المهم للغاية التأكد من أن طبيبك يعرف كل شيء عما تتناوله ، بما في ذلك أي شيء استعملته من الصيدلي أو متجر الأغذية الصحية. قد يكون من الضروري تغيير جرعة بعض الأدوية ، أو التوقف عن تناول أي شيء تمامًا.</p><p>&nbsp;</p><p><strong><u>أخبر طبيبك أذا كنت تتناول أحد الأدوية التالية:</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وسائل منع الحمل الهرمونية ، مثل: حبوب ، واللواصق ، والحقن أو الموانع المزروعة.</p><p>يؤثر عقار تجريتول على الطريقة التي تعمل بها وسائل منع الحمل في جسمك ، وقد تصاب بنزيف مفاجئ أو علامات. قد يجعل كذلك موانع الحمل أقل فعالية وسيكون هناك احتمالية حدوث الحمل. سيكون طبيبك قادرًا على تقديم النصح لك حول هذا الأمر ، ويجب عليك التفكير في استخدام وسائل منع الحمل الأخرى الفعالة.&nbsp;&nbsp;إذا كنت امرأة في سن القدرة على الإنجاب ، فعليك استخدام وسيلة فعالة لمنع الحمل طوال فترة العلاج ولمدة 28 يوم بعد التوقف عن العلاج.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج بالهرمونات البديلة (HRT) &nbsp;، عقار تجريتول يمكن أن يجعل العلاج بالهرمونات البديلة أقل فعالية.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي دواء لعلاج الاكتئاب أو القلق.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكورتيكوستيرويدات&nbsp;(الأدوية الستيرودية) قد تستعمل هذه الأدوية في الحالات الالتهابية مثل الربو وأمراض التهاب الأمعاء والعضلات وآلام المفاصل.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات التخثر لوقف تخثر الدم.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية لعلاج الالتهابات بما في ذلك الالتهابات الجلدية والسل (مثل: سيبروفلوكساسين).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الفطريات، لعلاج الالتهابات الفطرية.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مسكنات الآلام، ( تشمل: باراسيتامول، ، ديكستروبروبوكسيفين ، ترامادول ، ميثادون أو بوبرينورفين(.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى التي تعالج الصرع.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تعالج ضغط الدم المرتفع، أو علاج مشاكل القلب.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الهيستامين (الأدوية لعلاج الحساسية مثل حمى القش ، حكة ، الخ).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدرات البول (أقراص الماء)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;السيميتيدين أو أوميبرازول (أدوية لعلاج قرحة المعدة).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أيزوتريتينوين (دواء لعلاج حب الشباب)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميتوكلوبراميد أو أبريبتانت (الأدوية مكافحة للمرض).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأسيتازولاميد (دواء لعلاج الجلوكوما )المياه الزرقاء) - زيادة الضغط في العين).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدنازول أو الجسترينون (علاج التهاب بطانة الرحم).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الثيوفيلين أو الأمينوفيلين (يستخدم في علاج الربو).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السيكلوسبورين ، تاكروليموس أو سيروليموس (مثبطات مناعية ، تستخدم بعد عمليات زرع الأعضاء ، ولكن أيضًا في بعض الأحيان في علاج التهاب المفاصل أو الصدفية).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج انفصام الشخصية (مثل بالبيريدون ، أريبيبرازول).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; الأدوية السرطانية (مثل تيمسيروليموس، سيكلوفوسفاميد ، لاباتينيب).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; الأدوية المضادة للملاريا ، ميفلوكين.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; أدوية لعلاج فيروس نقص المناعة البشرية.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; ليفوثيروكسين (يستخدم لعلاج قصور الغدة الدرقية).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تادالافيل (يستخدم لعلاج العجز الجنسي).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; ألبيندازول (يستخدم لعلاج الديدان).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; البوبروبيون (يستخدم للمساعدة في التوقف عن التدخين).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; علاج بالأعشاب يسمى نبتة سانت جون.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; الأدوية أو المكملات الغذائية التي تحتوي على فيتامين ب (نيكوتيناميد).</p><p>&nbsp;</p><p><strong>د. الحمل والرضاعة</strong></p><p dir="RTL"><strong>الحمل:</strong></p><p>إذا كنت امرأة قادرة على الإنجاب ولا تخططين للحمل، فيجب عليك استخدام وسائل منع الحمل الفعالة أثناء العلاج بتجريتول. قد يؤثر تجريتول على طريقة عمل وسائل منع الحمل الهرمونية، مثل حبوب منع الحمل، ويجعلها أقل فعالية في منع الحمل. تحدثي إلى طبيبك الذي سيناقش معك نوع وسائل منع الحمل الأكثر ملاءمة للاستخدام أثناء تناول تجريتول. إذا أوقفت العلاج بتجريتول، يجب عليك الاستمرار في استخدام وسائل منع الحمل الفعالة لمدة أسبوعين إضافيين على الأقل بعد التوقف.</p><p>&nbsp;</p><p>إذا كنت حاملاً، أو تعتقدين أنك حامل، فيجب عليك إخبار طبيبك على الفور ومناقشة المخاطر المحتملة التي قد يشكلها دواء الصرع الذي تتناولينه على طفلك الذي لم يولد بعد.</p><p>&nbsp;</p><p>إذا كنت تخططين للحمل، فيجب عليك مناقشة علاج الصرع مع طبيبك في أقرب وقت ممكن قبل الحمل.</p><p>&nbsp;</p><p>يجب ألا تتوقف عن علاجك دون مناقشة ذلك مع طبيبك. قد يؤدي التوقف بشكل مفاجئ إلى حدوث نوبات صرع قد تلحق الضرر بك وبجنينك. لذا من المهم أن تظل حالة المرض تحت السيطرة بشكل جيد.</p><p>&nbsp;</p><p>يزيد تناول الكاربامازيبين أثناء الحمل من احتمالية إصابة الطفل بتشوهات خلقية جسدية. أظهرت الدراسات التي أجريت على النساء اللاتي تم علاجهن بالكاربامازيبين لعلاج الصرع أن 4-5 أطفال في المتوسط من كل 100 طفل سوف يعانون من تشوهات خلقية خطيرة عند الولادة. بالمقارنة مع 2 إلى 3 أطفال من كل 100 مولود لنساء لا يعانين من الصرع.</p><p>&nbsp;</p><p dir="RTL">يمكن أن تتطور هذه التشوهات في وقت مبكر من الحمل، حتى قبل أن تعرفي أنك حامل. تشمل الأنواع الأكثر شيوعًا من التشوهات الخلقية الرئيسية التي تم الابلاغ عنها بسبب كاربامازيبين السنسنة المشقوقة (حيث لا</p><p>تتطور عظام العمود الفقري بشكل صحيح)؛ تشوهات الوجه والجمجمة بما في ذلك الشفة/الحنك المشقوق؛ تشوهات الهيكل العظمي والقلب والمسالك البولية والأعضاء الجنسية.</p><p>&nbsp;</p><p>لقد وجدت الدراسات أن خطر حدوث تشوهات خلقية جسدية يزداد مع زيادة جرعات الكاربامازيبين. لذلك، من المهم أن يتم وصف أقل جرعة لك، بقدر الإمكان ، للسيطرة على الصرع.</p><p>&nbsp;</p><p>اسألي طبيبك عن تناول حمض الفوليك عند محاولة إنجاب طفل وأثناء الحمل. قد يقلل حمض الفوليك من المخاطر العامة لتشوهات الولادة الجسدية الخطيرة الموجودة في جميع حالات الحمل.</p><p>&nbsp;</p><p>إن تناول أكثر من علاج للصرع في نفس الوقت قد يزيد أيضًا من خطر حدوث تشوهات خلقية جسدية. يجب على طبيبك أن يفكر في استخدام علاج واحد للصرع للسيطرة على المرض لديك.</p><p>&nbsp;</p><p>لا يمكن استبعاد مشاكل النمو العصبي (نمو الدماغ) عند الأطفال الذين يولدون لنساء مصابات بالصرع يعالجن بالكاربامازيبين وحده أو مع أدوية أخرى مضادة للصرع أثناء الحمل.</p><p>&nbsp;</p><p dir="RTL">إذا كنت تتناول تجريتول أثناء الحمل، فإن طفلك يكون أيضًا معرضًا لخطر مشاكل النزيف بعد الولادة مباشرة. قد يعطيك طبيبك أنت وطفلك دواءً لمنع ذلك.</p><p>&nbsp;</p><p><strong>الرضاعة:</strong></p><p>يمكن للأمهات اللاتي يتناولن تجريتول أن يرضعن أطفالهن رضاعة طبيعية ، لكن يجب عليك إخبار الطبيب في أقرب وقت ممكن إذا كنت تعتقد أن الطفل يعاني من أعراض جانبية مثل النعاس المفرط ، حساسية بالجلد أو اصفرار الجلد والعينين، البول الداكن أو البراز الفاتح.</p><p dir="RTL">&nbsp;</p><p><strong>الخصوبة</strong></p><p>يجب عليك استخدام وسيلة فعالة لمنع الحمل طوال فترة العلاج بـتيجريتول ولمدة 28 يومًا بعد التوقف عن العلاج. قد يحدث عدم انتظام في الدورة الشهرية عند النساء اللواتي يتناولن موانع الحمل الهرمونية (أدوية تحديد النسل) وتيجريتول. قد تصبح موانع الحمل الهرمونية أقل فعالية ويجب أن تفكر في استخدام وسيلة منع حمل غير هرمونية مختلفة أو إضافية. اسأل طبيبك عن وسائل منع الحمل الفعالة.</p><p><strong>هـ. </strong><strong>تأثير تجريتول على القيادة واستخدام الآلات</strong></p><p><strong>&nbsp;</strong></p><p><strong>هل هناك أي مشاكل في القيادة أو استخدام الآلات؟</strong></p><p>يمكن أن يجعلك تجريتول تشعر بالدوار أو النعاس ، أو قد تتسبب في عدم وضوح الرؤية ، أو الرؤية المزدوجة ، أو قد تفتقر إلى التنسيق العضلي ، خاصة عند بدء العلاج أو عند تغيير الجرعة. إذا كنت متأثرًا بهذه الطريقة ، أو إذا تأثر بصرك ، فيجب عليك عدم القيادة أو تشغيل الآلات.</p><p><strong>&nbsp;</strong></p><p><strong>تحتوي أقراص تجريتول ممتدة المفعول على هيدروكسي ستيرات ماكروجولجليسيرول:</strong></p><p>هيدروكسي ستيرات ماكروجولجليسيرول قد يسبب اضطراب في المعدة والإسهال.</p><p>&nbsp;</p><p><strong>معلومات عن محتوى الصوديوم:</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 ملي مول صوديوم (23 مجم) لكل قرص ، وهذا يعني بشكل أساسي &quot;خالٍ من الصوديوم&quot;.</p><p><strong>تحذيرات أخرى</strong></p><ul><li>شرب الكحول قد يؤثر عليك أكثر من المعتاد. ناقش ما إذا كان يجب عليك التوقف عن الشرب مع طبيبك.</li><li>قد يؤدي تناول الجريب فروت أو شرب عصير الجريب فروت إلى زيادة فرص حدوث الأعراض الجانبية.</li><li>قد يجري طبيبك عدد من اختبارات الدم قبل البدء بتناول تجريتول ومن وقت لآخر أثناء العلاج. فهذا أمر معتاد ولا شيء يدعو للقلق.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تجريتول هو منتج طبي مضاد للصرع. يجب أن يبدأ العلاج باستخدام تجريتول ويشرف عليه طبيب ذو خبرة في استخدام المنتجات الطبية المضادة للصرع. اتبع تعليمات التخلص الواردة في القسم 6 (كيفية تخزين قرص تيجريتول ممتد المفعول).</p><p>&nbsp;</p><p><strong>سيخبرك الطبيب كم يجب أن يأخذ من عقار </strong><strong>تجريتول</strong><strong> ومتى يجب أخذه. اتبع دائمًا تعليماته بعناية. ستكون الجرعة على ملصق الصيدلي، تحقق الملصق بعناية. </strong></p><p><strong>من المهم أن تأخذ أقراص تجريتول في الأوقات المناسبة. إذا لم تكن متأكدًا ، اسأل طبيبك أو الصيدلي. </strong></p><p><strong>استمر في تناول الدواء الخاص بك طالما تم إخبارك ، ما لم تكن لديك أي مشاكل. في حال حدوث مشاكل، تحقق مع طبيبك.</strong></p><p>&nbsp;</p><p>سيبدأ طبيبك غالبًا تجريتول بجرعة منخفضة إلى حد ما والتي يمكن زيادتها لتناسبك بشكل فردي. الجرعة اللازمة تختلف بين المرضى. يمكنك تناول أقراص تجريتول أثناء أو بعد أو بين الوجبات. <strong>يجب ابتلاع القرص مع الماء وعدم المضغ</strong>. يُطلب منك عادة تناول جرعة مرتين أو ثلاث مرات في اليوم. إذا لزم الأمر ، يمكنك تقسيم الأقراص إلى النصف على طول الخط.</p><p>&nbsp;</p><p><strong><u>الجرعة لعلاج الصرع:</u></strong></p><p><strong>البالغين</strong>: 800 إلى 1200 مجم في اليوم، وقد يكون من اللازم زبادة الجرعة. إذا كنت من كبار السن فقد تحتاج إلى جرعة أقل.</p><p>&nbsp;</p><p><strong>الأطفال:</strong></p><p><strong>من عمر 5 إلى 10 سنوات</strong>: 400 &ndash; 600 مجم يوميًا &nbsp;</p><p><strong>من عمر 10 إلى 15 سنوات</strong>: 600 &ndash; 1000 مجم يوميًا&nbsp;</p><p>&nbsp;</p><p>لا يجب أن تؤخذ أقراص تجريتول للأطفال دون سن خمس سنوات.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>الجرعة لعلاج العصب الحائر:</u></strong></p><p>600-800 مجم يوميا. الحد الأقصى للجرعة اليومية هو 1200 مجم. إذا كنت من كبار السن ، فقد تحتاج إلى جرعة أقل.</p><p>&nbsp;</p><p><strong><u>الجرعة لعلاج تقلبات المزاج:</u></strong></p><p>400 &ndash; 600 مجم في اليوم.</p><p>&nbsp;</p><p><strong>أ. </strong><strong>الجرعة الزائدة من أقراص </strong><strong>تجريتول ممتدة المفعول </strong></p><p>إذا أخذت على سبيل الخطأ أقراص تجريتول أكثر مما ينبغي، <strong>أخبر بطبيبك أو قم بزيارة أقرب مستشفى</strong>، اصحب معك حزمة الدواء حتى يتمكن المسعفين من رؤية ما قد تناولته.</p><p>&nbsp;</p><p><strong>ب. </strong><strong>نسيان تناول جرعة من أقراص </strong><strong>تجريتول ممتدة المفعول </strong></p><p>إذا نسيت أن تأخذ إحدى الجرعات، خذها في أقرب وقت ممكن. ولكن إذا كان موعد جرعتك التالية قد اقترب، لا تأخذ الجرعة المنسية، وإنما ارجع إلى نظامك المعتاد في أخذ الجرعات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثلما يحدث مع جميع الأدوية، فإن المرضى الذين يستعملون تجريتول قد يتعرضون لحدوث آثار جانبية، غير أنها لا تحدث لجميع الأشخاص بالعادة.</p><p>&nbsp;</p><p><strong><u>بعض الآثار الجانبية قد تكون خطيرة</u></strong></p><p><strong>توقف عن استعمال أقراص تجريتول ممتدة المفعول، وأخبر طبيبك فورًا عند ملاحظة الأعراض التالية:</strong></p><ul><li>ردود فعل خطيرة على الجلد مثل الطفح الجلدي أو احمرار الجلد أو ظهور تقرحات في الشفاه أو العينين أو الفم أو تقشير الجلد المصحوب بالحمى. قد تكون ردود الفعل هذه أكثرانتشار في المرضى من أصل صيني أو تايلندي</li><li>تقرحات الفم، أو كدمات غير متوقعة، أو نزيف</li><li>التهاب الحلق أو ارتفاع درجة الحرارة ، أو كليهما</li><li>اصفرار بشرتك أو بياض عينيك</li><li>تورم الكاحلين والقدمين أو أسفل الساقين</li><li>أي من علامات المرض العصبي أو الارتباك</li><li>ألم في المفاصل والعضلات ، طفح جلدي عبر الأنف والخدين ومشاكل في التنفس (قد تكون هذه علامات على رد فعل نادر يعرف باسم الذئبة الحمراء)</li><li>الحمى ، الطفح الجلدي ، ألم المفاصل ، نتائج غير طبيعية في اختبارات وظائف الدم والكبد (قد تكون هذه علامات على اضطراب حساسية متعدد الأعضاء)</li><li>تشنج قصبي مع الصفير والسعال ، وصعوبة في التنفس ، والشعور بالإغماء ، أو الطفح الجلدي ، أو الحكة أو تورم في الوجه (قد تكون هذه علامات على الحساسية الشديدة)</li><li>ألم في المنطقة القريبة من المعدة</li><li>تعاني من السقوط بسبب الدوخة والدوار وانخفاض ضغط الدم والارتباك.</li></ul><p><strong>&nbsp;</strong></p><p><strong><u>تم الإبلاغ عن الآثار الجانبية المذكورة أدناه:</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><em>شائعة جدًا (هذه الآثار الجانبية قد تصيب أكثر من شخص واحد من بين 10 أشخاص)</em></strong></p><p>قلة الكريات البيض (عدد أقل من الخلايا التي تكافح العدوى مما يجعل من السهل التقاط العدوى) ؛ الدوخة والتعب. الشعور بعدم الاستقرار أو إيجاد صعوبة في التحكم بالحركات ؛ الشعور بالمرض. تغييرات في مستويات انزيمات الكبد (عادة دون أي أعراض) ؛ ردود فعل الجلد التي قد تكون شديدة.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><em>شائعة (هذه الآثار الجانبية قد تصيب &nbsp;1 من بين 10 أشخاص)</em></strong></p><p>التغييرات في الدم بما في ذلك الميل المتزايد للكدمات أو النزيف ؛ احتباس السوائل والتورم ؛ زيادة الوزن. انخفاض الصوديوم في الدم مما قد يؤدي إلى الارتباك ؛ صداع ؛ رؤية مزدوجة أو غير واضحة ؛ جفاف الفم.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><em>غير شائعة (هذه الآثار الجانبية قد تصيب 1 من بين 100 أشخاص)</em></strong></p><p>حركات لا إرادية غير طبيعية بما في ذلك الهزات أو التشنجات؛ حركات غير طبيعية للعين. إسهال؛ الإمساك.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><em>نادرة (هذه الآثار الجانبية قد تصيب 1 من بين 1000 أشخاص)</em></strong></p><p>مرض الغدد اللمفاوية. نقص حمض الفوليك. رد الفعل التحسسي المعمم بما في ذلك الطفح الجلدي وآلام المفاصل والحمى ومشاكل في الكلى والأعضاء الأخرى ؛ الهلوسة. اكتئاب؛ فقدان الشهية؛ الأرق؛ عدوان؛ تهيج. الارتباك. اضطرابات الكلام. تنميل أو وخز في اليدين والقدمين ؛ ضعف العضلات. ارتفاع ضغط الدم (مما قد يجعلك تشعر بالدوار ، مع توريد الوجه، والصداع ، والتعب والعصبية) ؛ انخفاض ضغط الدم (الأعراض التي تشعر بها هي الإغماء ، صداع ، والدوار ، والارتباك ، وجود عدم وضوح الرؤية) ؛ التغييرات في ضربات القلب ؛ آلام في المعدة. مشاكل في الكبد بما في ذلك اليرقان. أعراض مرض الذئبة الحمراء.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><em>نادرة جدًا (هذه الآثار الجانبية قد تصيب 1 من بين 10000 أشخاص)</em></strong></p><p>التغييرات في تكوين الدم بما في ذلك فقر الدم. البورفيريا. التهاب السحايا. تورم الثديين وتصريف الحليب الذي قد يحدث في كل من الذكور والإناث ؛ نتائج غير طبيعية لوظائف الغدة الدرقية. لين العظام (التي يمكن ملاحظتها على أنها ألم على المشي والركوع للعظام الطويلة في الساقين) ؛ هشاشة العظام؛ زيادة مستويات الدهون في الدم. اضطرابات في حاسة الذوق. التهاب الملتحمة؛ المياه الزرقاء في العين (جلوكوما)؛ إعتام عدسة العين. اضطرابات السمع. مشاكل في القلب والدورة الدموية بما في ذلك تجلط الأوردة العميقة (DVT) ، ويمكن أن تشمل أعراضه التهاب والألم والتورم والسخونة وتغير لون الجلد والأوردة السطحية البارزة ؛ مشاكل في الرئة أو التنفس ، التفاعلات الجلدية الشديدة بما في ذلك متلازمة ستيفنز جونسون (قد تكون هذه التفاعلات أكثر تكرار في المرضى من أصل صيني أو تايلندي) ؛ التهاب الفم أو اللسان. تليف كبدى؛ زيادة حساسية الجلد لأشعة الشمس. تغييرات في تصبغ الجلد. حب الشباب؛ التعرق المفرط. تساقط شعر؛ زيادة نمو الشعر على الجسم والوجه ؛ ألم العضلات أو تشنج. الصعوبات الجنسية التي قد تشمل انخفاض خصوبة الذكور ، وفقدان الرغبة الجنسية أو العجز الجنسي ؛ فشل كلوي؛ بقع الدم في البول. زيادة أو نقصان الرغبة في تمرير البول أو صعوبة في التبول.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>غير معروفة (لا يمكن تقدير معدل تكرارها&nbsp; من خلال البيانات المتاحة):</strong></p><p><strong>تم الإبلاغ عن الحالات التالية كذلك، لكن لا يمكن تحديد تكرار هذه الأعراض من المعلومات المتاحة:</strong></p><p>ردود الفعل الجلدية الشديدة ، يرافقه شعور بالتوعك والتغيرات في نتائج تحاليل الدم. الإسهال، وآلام البطن والحمى (علامات التهاب القولون) ، وتنشيط عدوى فيروس الهربس (يمكن أن تكون خطيرة عند ضعف الجهاز المناعي) ، وفقدان كامل للأظافر ، والكسور ، وانخفاض في قياس كثافة العظام ، والدوار، فقدان الذاكرة ، الكدمات الأرجوانية أو الأرجواني المحمر التي قد تكون مصاحبة للحكة.</p><p>&nbsp;</p><p><strong>لا تنزعج من هذه القائمة. معظم الناس يتناولون </strong><strong>أقراص تجريتول ممتدة المفعول</strong><strong> دون أي مشاكل.</strong></p><p>&nbsp;</p><p><strong>إذا أصبحت أي من الأعراض مزعجة ، أو إذا لاحظت أي شيء آخر لم يرد ذكره هنا ، فيرجى إخبار إلى طبيبك الذي قد يرغب في إعطائك دواء مختلف.</strong></p><p>&nbsp;</p><p>هناك تقاريرعن مشاكل في العظام بما في ذلك هشاشة العظام وآلام العظام (ترقق العظم) والكسور. استشر طبيبك أو الصيدلي إذا كنت تتناول أدوية مضادة للصرع على المدى الطويل ، أو لديك تاريخ من مرض هشاشة العظام ، أو تتناول أدوية منشطة (ستيرودية(steroids</p><p>&nbsp;</p><p><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p>إذا تعرضت لأي من الأعراض الجانبية، فأخبر طبيبك أو الصيدلي. حتى وإن لم يكن مذكور في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يخزن فوق حرارة 30 درجة مئوية</li><li>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحفظ في العبوة الأصلية لحمايتها من الرطوبة.</li><li>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ بعيداً عن متناول ونظر الأطفال.</li><li>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي استعمال أقراص تجريتول بعد تاريخ انتهاء الصلاحية المذكور على مُلصَق العبوة.</li></ul><p dir="RTL"><strong><u>التعامل مع العلاج:</u></strong></p><p dir="RTL">تجريتول هو منتج طبي مضاد للصرع. استخدم منطقة مخصصة لتخزين الأدوية وتقييد الوصول إليها في أماكن الرعاية الصحية على الموظفين المصرح لهم فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>التخلص من العلاج:</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب التخلص من أي منتج طبي أو نفايات غير مستخدمة وفقًا للمتطلبات المحلية. يجب غسل اليدين جيداً بالماء بعد التخلص من أي منتج طبي أو نفايات غير مستخدمة.</p><ul><li>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك طبيبك بالتوقف عن تناول الدواء ، فالرجاء أخذ أي ما تبقى إلى الصيدلي للتخلص منه.</li><li>لا تتخلص منه بالماء أو النفايات المنزلية العادية. هذا سوف يساعد على حماية البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي الأقراص على تركيزين إما 200 مجم أو 400 مجم من المادة الفعالة كاربامازيبين.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الأقراص تحتوي كذلك على مواد أخر:</strong> ثاني أكسيد السيليكون الغروي مفرق المياه،&nbsp; إيثيل سلولوز &nbsp;، مايكرو كريستال سيليلوز، إيثيل أكريليت / ميثيل ميثاكريلات كوبوليمر ، ستيرات المغنيسيوم ، كروسكارميلوز الصوديوم من النوع أ ، التلك ، هيدروكسي بروبيل ميثيل سيليلوز ، جليسريل بوليكسي إيثيلين ستيرات الجلايكول، أكسيد الحديد الأحمر والأصفر (E172) وثاني أكسيد التيتانيوم (E171).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>تجريتول سي آر أقراص ممتدة المفعول 200 مجم هي أقراص بيضاوية ، برتقالية اللون مع كتابة على كل جانب. جانب واحد يحمل طباعة &quot;HC&quot; ، والآخر &quot;CG&quot;.</p><p>&nbsp;</p><p>حجم العبوة هو 50</p><p>&nbsp;</p><p>تجريتول سي آر أقراص ممتدة المفعول 400 مجم هي أقراص بيضاوية ذات لون بني-برتقالي ولها كتابة على كل جانب. جانب واحد يحمل طباعة &quot;ENE / ENE&quot; ، والآخر &quot;CG / CG&quot;.</p><p>&nbsp;</p><p>حجم العبوة هو 30</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p>www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2024
هـ.  للإبلاغ عن الأعراض الجانبية : 
•	المملكة العربية السعودية

   - المركز الوطني للتيقظ والسلامة الدوائية (NPC)
•	مركز اتصال الهيئة السعودية للغذاء والدواء: 19999
•	البريد الالكتروني: npc.drug@sfda.gov.sa
•	الموقع الالكتروني: https://ade.sfda.gov.sa

-	شركة نوفارتس - السعودية - قسم سلامة المرضى:
•	الهاتف المجاني: 8001240078
•	الهاتف:  +966112658100
•	الفاكس: +966112658107
•	البريد الالكتروني: adverse.events@novartis.com

·	دول مجلس التَّعاون الخليجي الأخرى: 
- يُرجى الاتصال بسلطات الاختصاص المعنية

و.  للإبلاغ عن أي شكوى:  complaints.ksa@novartis.com

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tegretol CR Prolonged Release 200mg Tablets
Tegretol CR Prolonged Release 400mg Tablets


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The active ingredient is 5H-dibenzo[b,f]azepine-5-carboxamide.
Each coated tablet contains 200mg or 400 carbamazepine Ph.Eur.

For a full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged Release Tablet.

200mg: Tablets which are beige-orange, oval, slightly biconvex, coated tablets with a score on each side.  One side bears the imprint “H/C”, the other “C/G”.
400 mg: Tablets which are brownish-orange, oval, slightly biconvex, coated tablets with a score on each side.  One side bears the imprint “ENE/ENE”, the other “CG/CG”.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Epilepsy - generalised tonic-clonic and partial seizures.&nbsp; Tegretol Prolonged Release is indicated in newly diagnosed patients with epilepsy and in those patients who are uncontrolled or unable to tolerate their current anti-convulsant therapy.</p><p>&nbsp;</p><p>Note:&nbsp; Carbamazepine is not usually effective in absences (petit mal) and myoclonic seizures.&nbsp; Moreover, anecdotal evidence suggests that seizure exacerbation may occur in patients with atypical absences.</p><p>&nbsp;</p><p>The paroxysmal pain of trigeminal neuralgia.</p><p>&nbsp;</p><p>For the prophylaxis of manic-depressive psychoses in patients unresponsive to lithium therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tegretol Prolonged Release is given orally, generally in the same total daily dose as conventional Tegretol dosage forms but usually in two divided doses.&nbsp; In a few patients when changing from other oral dosage forms of Tegretol to Tegretol Prolonged Release the total daily dose may need to be increased, particularly when it is used in polytherapy.&nbsp; When starting treatment with Tegretol Prolonged Release in monotherapy, 100-200mg once or twice daily is recommended.&nbsp; This may be followed by a slow increase in dosage until the best response is obtained, often 800-1200mg daily.&nbsp; In some instances, 1600mg or even 2000mg daily may be necessary.</p><p>&nbsp;</p><p>Tegretol is an anti-epileptic medical product. (See section 6.6 Special precautions for disposal.)</p><p>&nbsp;</p><p>Tegretol Prolonged Release (either the whole or half divisible tablet as prescribed), should <u>not</u> be chewed but should be swallowed with a little liquid, before, during or between meals.&nbsp; The divisible tablet presentation enables flexibility of dosing to be achieved.</p><p>&nbsp;</p><p>Before deciding to initiate treatment, patients of Han Chinese and Thai origin should whenever possible be screened for HLA-B*1502 as this allele strongly predicts the risk of severe carbamazepine-associated Stevens-Johnson syndrome (See information on genetic testings and cutaneous reactions in<strong> </strong>section 4.4).</p><p>&nbsp;</p><p><em>Epilepsy:</em></p><p>&nbsp;</p><p>The dose of carbamazepine should be adjusted to the needs of the individual patient to achieve adequate control of seizures. Determination of plasma levels may help in establishing the optimum dosage. In the treatment of epilepsy, the dose of carbamazepine usually requires total plasma-carbamazepine concentrations of about 4 to 12 micrograms/mL (17 to 50 micromoles/litre) (see warnings and precautions).</p><p>&nbsp;</p><p><em>Adults:&nbsp; </em>It is advised that with all formulations of Tegretol, a gradually increasing dosage scheme is used and this should be adjusted to suit the needs of the individual patient.&nbsp;&nbsp;</p><p>&nbsp;</p><p><em>Elderly </em><em>population (65 years or above)</em><em>:</em>&nbsp;&nbsp; Due to the potential for drug interactions, the dosage of Tegretol should be selected with caution in elderly patients.</p><p>&nbsp;</p><p><em>Children </em><em>and adolescents</em><em>:</em>&nbsp; It is advised that with all formulations of Tegretol, a gradually increasing dosage scheme is used and this should be adjusted to suit the needs of the individual patient.&nbsp;</p><p>Usual dosage 10-20mg/kg bodyweight daily in several divided doses.</p><p>&nbsp;</p><p>Age &nbsp;&nbsp;&nbsp;&nbsp; up to 5 years:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tegretol Prolonged Release Tablets are not recommended</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5-10 years:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 400-600mg daily</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10-15 years:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 600-1000mg</p><p>&gt;15 years of age: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 800 to 1200mg daily (same as adult dose)</p><p><strong>&nbsp;</strong></p><p><u>Maximum recommended dose</u></p><p>Up to 6 years of age: 35mg/kg/day</p><p>6 to 15 years of age: 1000mg/day</p><p>&gt;15 years of age: 1200mg/day.</p><p>&nbsp;</p><p>Wherever possible, Tegretol Prolonged Release should be used as the sole drug anti-epileptic agent but if used in polytherapy, the same incremental dosage pattern is advised.</p><p>&nbsp;</p><p>When Tegretol is added to existing antiepileptic therapy, this should be done gradually while maintaining or, if necessary, adapting the dosage of the other antiepileptic(s) (see 4.5 Interaction with other medicinal products and other forms of interaction).</p><p>&nbsp;</p><p><em>Trigeminal neuralgia:</em></p><p>&nbsp;</p><p>Slowly raise the initial dosage of 200-400mg daily until freedom from pain is achieved (normally at 200mg 3-4 times daily).&nbsp; In the majority of&nbsp; patients a dosage of 200mg 3 or 4 times a day is sufficient to maintain a pain free state.&nbsp; In some instances, doses of 1600mg Tegretol daily may be needed.&nbsp; However, once the pain is in remission, the dosage should be gradually reduced to the lowest possible maintenance level.&nbsp; Maximum recommended dose is 1200mg/day. When pain relief has been obtained, attempts should be made to gradually discontinue therapy, until another attack occurs.</p><p>&nbsp;</p><p><em>Elderly</em><em> population (65 years of age or above)</em><em>:&nbsp; </em></p><p><em>&nbsp;</em></p><p><em>Dosage in Trigeminal neuralgia</em></p><p>Due to drug interactions and different antiepileptic drug pharmacokinetics, the dosage of Tegretol should be selected with caution in elderly patients.</p><p>&nbsp;</p><p>In elderly patients, an initial dose of 100mg twice daily is recommended. The initial dosage of 100mg twice daily should be slowly raised daily until freedom from pain is achieved (normally at 200mg 3 to 4 times daily). The dosage should then be gradually reduced to the lowest possible maintenance level. Maximum recommended dose is 1200mg/day. When pain relief has been obtained, attempts should be made to gradually discontinue therapy, until another attack occurs.</p><p>&nbsp;</p><p><em>For the prophylaxis of&nbsp; manic depressive psychosis in patients unresponsive to lithium therapy</em>:</p><p>&nbsp;</p><p>Initial starting dose of 400mg daily, in divided doses, increasing gradually until symptoms are controlled or a total of 1600mg given in divided doses is reached.&nbsp; The usual dosage range is 400-600mg daily, given in divided doses.</p><p>&nbsp;</p><p><em>Special populations</em></p><p><em>&nbsp;</em></p><p><em>Renal impairment / Hepatic impairment</em></p><p>No data are available on the pharmacokinetics of carbamazepine in patients with impaired hepatic or renal function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Known hypersensitivity to carbamazepine or structurally related drugs (e.g. tricyclic antidepressants) or any other component of the formulation.  

Patients with atrioventricular block, a history of bone marrow depression or a history of hepatic porphyrias (e.g. acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda). 

The use of Tegretol is contraindicated in combination with monoamine oxidase inhibitors (MAOIs) (see section 4.5 Interaction with other medicinal products and other forms of interaction).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Warnings</em></strong></p><p>Agranulocytosis and aplastic anaemia have been associated with Tegretol; however, due to the very low incidence of these conditions, meaningful risk estimates for Tegretol are difficult to obtain.&nbsp; The overall risk in the general untreated population has been estimated at 4.7 persons per million per year for agranulocytosis and 2.0 persons per million per year for aplastic anaemia.</p><p>&nbsp;</p><p>Decreased platelet or white blood cell counts occur occasionally to frequently in association with the use of Tegretol.&nbsp; Nonetheless, complete pre-treatment blood counts, including platelets and possibly reticulocytes and serum iron, should be obtained as a baseline, and periodically thereafter.&nbsp;</p><p>&nbsp;</p><p>Patients and their relatives should be made aware of early toxic signs and symptoms indicative of a potential haematological problem, as well as symptoms of dermatological or hepatic reactions.&nbsp; If reactions such as fever, sore throat, rash, ulcers in the mouth, easy bruising, petechial or purpuric haemorrhage appear, the patient should be advised to consult the physician immediately.&nbsp;</p><p>&nbsp;</p><p>If the white blood cell or platelet count is definitely low or decreased during treatment, the patient and the complete blood count should be closely monitored (see Section 4.8 Undesirable Effects).&nbsp;&nbsp; However, treatment with Tegretol should be discontinued if the patient develops leucopenia which is severe, progressive or accompanied by clinical manifestations, e.g. fever or sore throat.&nbsp; Tegretol should also be discontinued if any evidence of significant bone marrow depression appears.</p><p>&nbsp;</p><p>Liver function tests should also be performed before commencing treatment and periodically thereafter, particularly in patients with a history of liver disease and in elderly patients.&nbsp; The drug should be withdrawn immediately in cases of aggravated liver dysfunction or acute liver disease.</p><p>&nbsp;</p><p>Some liver function tests in patients receiving carbamazepine may be found to be abnormal, particularly gamma glutamyl transferase.&nbsp; This is probably due to hepatic enzyme induction.&nbsp; Enzyme induction may also produce modest elevations in alkaline phosphatase.&nbsp; These enhancements of hepatic metabolising capacity are not an indication for the withdrawal of carbamazepine.</p><p>&nbsp;</p><p>Severe hepatic reactions to carbamazepine occur very rarely.&nbsp; The development of signs and symptoms of liver dysfunction or active liver disease should be urgently evaluated and treatment with Tegretol suspended pending the outcome of the evaluation.</p><p>&nbsp;</p><p>Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents in several indications.&nbsp; A meta-analysis of randomised placebo-controlled trials of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour.&nbsp; The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for carbamazepine.</p><p>Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered.&nbsp; Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.</p><p>Serious dermatological reactions, including toxic epidermal necrolysis (TEN: also known as Lyell&rsquo;s syndrome) and Stevens Johnson syndrome (SJS) have been reported very rarely with Tegretol.&nbsp; Patients with serious dermatological reactions may require hospitalization, as these conditions may be life-threatening and may be fatal.&nbsp; Most of the SJS/TEN cases appear in the first few months of treatment with Tegretol. These reactions are estimated to occur in 1 to 6 per 10,000 new users in countries with mainly Caucasian populations. If signs and symptoms suggestive of severe skin reactions (e.g. SJS, Lyell&#39;s syndrome/TEN) appear, Tegretol should be withdrawn at once and alternative therapy should be considered.</p><p>&nbsp;</p><p><strong><em>Cutaneous reactions</em></strong></p><p>Serious and sometimes fatal cutaneous reactions including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) have been reported during treatment with carbamazepine. These reactions are estimated to occur in 1-6 per 10 000 new users in countries with mainly Caucasian populations, but the risk in some Asian countries is estimated to be about 10 times higher.</p><p>&nbsp;</p><p>There is growing evidence of the role of different HLA alleles in predisposing patients to immune-mediated adverse reactions (see section 4.2).</p><p>&nbsp;</p><p><strong><em>HLA-B*1502 allele -&nbsp; in Han Chinese, Thai and other Asian populations </em></strong></p><p>HLA-B*1502 in individuals of Han Chinese and Thai origin has been shown to be strongly associated with the risk of developing Stevens-Johnson syndrome (SJS) when treated with carbamazepine. The prevalence of HLA-B*1502 carrier is about 10% in Han Chinese and Thai populations. Whenever possible, these individuals should be screened for this allele before starting treatment with carbamazepine (see section 4.2). If these individuals test positive, carbamazepine should not be started unless there is no other therapeutic option.&nbsp; Tested patients who are found to be negative for HLA-B*1502 have a low risk of SJS, although the reactions may still very rarely occur.</p><p>&nbsp;</p><p>There are some data that suggest an increased risk of serious carbamazepine-associated TEN/SJS in other Asian populations. Because of the prevalence of this allele in other Asian populations (e.g. above 15% in the Philippines and Malaysia), testing genetically at risk populations for the presence of HLA-B*1502 may be considered.</p><p>&nbsp;</p><p>The prevalence of the HLA-B*1502 allele is negligible in e.g. European descent, African, Hispanic populations sampled, and in Japanese and Koreans (&lt; 1%).</p><p>&nbsp;</p><p><strong><em>HLA-A*3101 allele -&nbsp; European descent and Japanese populations </em></strong></p><p>There are some data that suggest HLA-A*3101 is associated with an increased risk of carbamazepine induced cutaneous adverse drug reactions including SJS, TEN, Drug rash with eosinophilia (DRESS), or less severe acute generalized exanthematous pustulosis (AGEP) and maculopapular rash (see section 4.8) in people of European descent and the Japanese.</p><p>&nbsp;</p><p>The frequency of the HLA-A*3101 allele varies widely between ethnic populations. HLA-A*3101 allele has a prevalence of 2 to 5% in European populations and about 10% in Japanese population.</p><p>&nbsp;</p><p>The presence of HLA-A*3101 allele may increase the risk for carbamazepine induced cutaneous reactions (mostly less severe) from 5.0% in general population to 26.0% among subjects of Northern European ancestry, whereas its absence may reduce the risk from 5.0% to 3.8%.</p><p>&nbsp;</p><p>There are insufficient data supporting a recommendation for HLA-A*3101 screening before starting carbamazepine treatment.</p><p>&nbsp;</p><p>If patients of European descent or Japanese origin are known to be positive for HLA-A*3101 allele, the use of carbamazepine may be considered if the benefits are thought to exceed risks.</p><p>&nbsp;</p><p><strong><em>Other dermatologic reactions</em></strong></p><p>Mild skin reactions e.g. isolated macular or maculopapular exanthema, can also occur and are mostly transient and not hazardous. They usually disappear within a few days<strong> </strong>or weeks, either during the continued course of treatment or following a decrease in dosage. However, since it may be difficult to differentiate the early signs of more serious skin reactions from mild transient reactions, the patient should be kept under close surveillance with consideration given to immediately withdrawing the drug should the reaction worsen with continued use.</p><p>&nbsp;</p><p>The HLA-B*1502 allele has not been found to predict risk of less severe adverse cutaneous reactions from carbamazepine, such as anticonvulsant hypersensitivity syndrome or non-serious rash (maculopapular eruption).</p><p>&nbsp;</p><p><strong><em>Hypersensitivity</em></strong></p><p>Class I (immediate) hypersensitivity reactions including rash, pruritus, urticaria, angioedema and reports of anaphylaxis have been reported with Tegretol. If a patient develops these reactions after treatment with Tegretol, the drug must be discontinued, and an alternative treatment started.</p><p>&nbsp;</p><p>Tegretol may trigger hypersensitivity reactions, including Drug Rash with Eosinophilia and Systemic Symptoms (DRESS),<strong> </strong>reactivation of HHV6 associated with DRESS, a delayed multi-organ hypersensitivity disorder with fever, rash, vasculitis, lymphadenopathy, pseudo lymphoma, arthralgia, leukopenia, eosinophilia, hepato-splenomegaly, abnormal liver function tests and vanishing bile duct syndrome (destruction and disappearance of the intrahepatic bile ducts), that may occur in various combinations. Other organs may also be affected (e.g. lungs, kidneys, pancreas, myocardium, colon) see section 4.8 Undesirable Effects.</p><p>&nbsp;</p><p>In general, if signs and symptoms suggestive of hypersensitivity reactions occur, Tegretol should be withdrawn immediately.</p><p>&nbsp;</p><p>Patients who have exhibited hypersensitivity reactions to carbamazepine should be informed that 25-30 % of these&nbsp; patients may experience hypersensitivity reactions with oxacarbazepine (Trileptal).</p><p>&nbsp;</p><p>Cross-hypersensitivity can occur between carbamazepine and aromatic antiepileptic drugs (e.g. phenytoin, primidone and phenobarbital).</p><p>&nbsp;</p><p>Tegretol should be used with caution in patients with mixed seizures which include absences, either typical or atypical.&nbsp; In all these conditions, Tegretol may exacerbate seizures.&nbsp; In case of exacerbation of seizures, Tegretol should be discontinued.</p><p>&nbsp;</p><p>An increase in seizure frequency may occur during switchover from an oral formulation to suppositories.</p><p>&nbsp;</p><p><strong><em>Dose reduction and withdrawal effects:</em></strong></p><p>Abrupt withdrawal of Tegretol may precipitate seizures, therefore carbamazepine withdrawal should be gradual. If treatment with Tegretol has to be withdrawn abruptly in a patient with epilepsy, the changeover to another anti-epileptic drug should if necessary be effected under the cover of a suitable drug.</p><p>&nbsp;</p><p><strong><em>Pregnancy and females of reproductive potential</em></strong></p><p>Carbamazepine may cause foetal harm when administered to a pregnant woman. Prenatal exposure to carbamazepine may increase the risks for major congenital malformations and other adverse development outcomes (see Section 4.6 Fertility, pregnancy and lactation).</p><p>&nbsp;</p><p>Carbamazepine should not be used in women of childbearing potential unless the benefit is judged to outweigh the risks following careful consideration of alternative suitable treatment options.</p><p>Women of childbearing potential should be fully informed of the potential risk to the foetus if they take carbamazepine during pregnancy.</p><p>&nbsp;</p><p>Before the initiation of treatment with carbamazepine in a woman of childbearing potential, pregnancy testing should be considered.</p><p>Women of childbearing potential should use highly effective contraception during treatment and for at least two weeks after stopping treatment. Due to enzyme induction, carbamazepine may result in a failure of the therapeutic effect of hormonal contraceptives, therefore, women of childbearing potential should be counselled regarding the use of other effective contraceptive methods (see Sections 4.5 and 4.6 Fertility, pregnancy and lactation).</p><p>&nbsp;</p><p>Women of childbearing potential should be counselled regarding the need to consult their physician as soon as they are planning a pregnancy to discuss switching to alternative treatments prior to conception and before contraception is discontinued (see Section 4.6 Fertility, pregnancy and lactation).</p><p>Women of childbearing potential should be counselled to contact the doctor immediately if they become pregnant or think they might be&nbsp;pregnant and are taking carbamazepine.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>Endocrinological effects</em></strong></p><p>Breakthrough bleeding has been reported in women taking Tegretol while using hormonal contraceptives. The reliability of hormonal contraceptives may be adversely affected by Tegretol and women of child-bearing potential should be advised to consider using alternative forms of birth control while taking Tegretol.</p><p>&nbsp;</p><p>Patients taking Tegretol and requiring hormonal contraception should receive a preparation containing not less than 50&micro;g oestrogen or use of some alternative non-hormonal method of contraception should be considered.<strong>&nbsp; </strong>&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p><strong><em>Monitoring of plasma levels</em></strong></p><p>Although correlations between dosages and plasma levels of carbamazepine, and between plasma levels and clinical efficacy or tolerability are rather tenuous<strong>,</strong> monitoring of the plasma levels may be useful in the following conditions:&nbsp; dramatic increase in seizure frequency/verification of patient compliance; during pregnancy; when treating children or adolescents; in suspected absorption disorders; in suspected toxicity when more than one drug is being used (see 4.5 Interaction with other medicinal products and other forms of interaction).</p><p>&nbsp;</p><p><strong><em>Precautions</em></strong></p><p>Tegretol should be prescribed only after a critical benefit-risk appraisal and under close monitoring in patients with a history of cardiac, hepatic or renal damage, adverse haematological reactions to other drugs, or interrupted courses of therapy with Tegretol.&nbsp;</p><p>&nbsp;</p><p>Baseline and periodic complete urinalysis and BUN determinations are recommended.&nbsp;</p><p>&nbsp;</p><p><strong><em>Hyponatremia</em></strong></p><p>Hyponatremia is known to occur with carbamazepine. In patients with pre-existing renal conditions associated with low sodium or in patients treated concomitantly with sodium-lowering medicinal products (e.g. diuretics, medicinal products associated with inappropriate ADH secretion), serum sodium levels should be measured prior to initiating carbamazepine therapy. Thereafter, serum sodium levels should be measured after approximately two weeks and then at monthly intervals for the first three months during therapy, or according to clinical need. These risk factors may apply especially to elderly patients. If hyponatraemia is observed, water restriction is an important counter-measurement if clinically indicated.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Hypothyroidism</em></strong></p><p>Carbamazepine may reduce serum concentrations of thyroid hormones through enzyme induction requiring an increase in dose of thyroid replacement therapy in patients with hypothyroidism. Hence thyroid function monitoring is suggested to adjust the dosage of thyroid replacement therapy.</p><p><strong>&nbsp;</strong></p><p><strong><em>Anticholinergic effects</em></strong></p><p>Tegretol has shown mild anticholinergic activity; patients with increased intraocular pressure and urinary retention should therefore be closely observed during therapy (see section 4.8).</p><p>&nbsp;</p><p><strong><em>Psychiatric effects</em></strong></p><p>The possibility of activation of a latent psychosis and, in elderly patients, of confusion or agitation should be borne in mind.&nbsp;</p><p>&nbsp;</p><p><strong><em>Interactions</em></strong></p><p>Co-administration of inhibitors of CYP3A4 or inhibitors of epoxide hydrolase with carbamazepine can induce adverse reactions (increase of carbamazepine or carbamazepine-10,11 epoxide plasma concentrations, respectively). The dosage of Tegretol should be adjusted accordingly and/or the plasma levels monitored.</p><p>&nbsp;</p><p>Co-administration of CYP3A4 inducers with carbamazepine may decrease carbamazepine plasma concentrations and its therapeutic effect, while discontinuation of a CYP3A4 inducer may increase carbamazepine plasma concentrations. The dosage of Tegretol may have to be adjusted.</p><p>&nbsp;</p><p>Carbamazepine is a potent inducer of CYP3A4 and other phase I and phase II enzyme systems in the liver, and may therefore reduce plasma concentrations of co-medications mainly metabolized by CYP3A4 by induction of their metabolism. See section 4.5 Interactions.</p><p>&nbsp;</p><p>Female patients of child-bearing potential should be warned that the concurrent use of Tegretol with hormonal contraceptives may render this type of contraceptive ineffective (see sections 4.5&nbsp;Interactions and 4.6 Fertility, pregnancy and lactation). Alternative non-hormonal forms of contraception are recommended when using Tegretol.</p><p>&nbsp;</p><p><strong><em>&nbsp;&nbsp; Falls</em></strong></p><p>Tegretol treatment has been associated with ataxia, dizziness, somnolence, hypotension, confusional state, sedation (see section 4.8 Undesirable effects) which may lead to falls and, consequently fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete risk assessment of fall should be considered recurrently for patients on long-term Tegretol treatment.</p><p>&nbsp;</p><p><strong><em>Tegretol Prolonged Release Tablets contain sodium</em></strong></p><p>This medicine contains less than 1mmol sodium (23mg) per tablet, that is to say essentially &lsquo;sodium free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cytochrome P450 3A4 (CYP 3A4) is the main enzyme catalysing formation of the active metabolite&nbsp; carbamazepine 10, 11-epoxide.&nbsp; Co-administration of inhibitors of CYP 3A4 may result in increased&nbsp; carbamazepine plasma concentrations which could induce adverse reactions.&nbsp; Co-administration of CYP 3A4 inducers might increase the rate of carbamazepine&nbsp; metabolism, thus leading to&nbsp; potential decreases in the carbamazepine serum level and therapeutic effect.</p><p>Similarly, discontinuation of a CYP3A4 inducer may decrease the rate of metabolism of carbamazepine, leading to an increase in carbamazepine plasma levels.</p><p>Carbamazepine is a potent inducer of CYP3A4 and other phase I and phase II enzyme systems in the liver, and may therefore reduce plasma concentrations of co-medications mainly metabolized by CYP3A4 by induction of their metabolism.</p><p>Human microsomal epoxide hydrolase has been identified as the enzyme responsible for the formation of the 10,11-transdiol derivative from carbamazepine-10,11 epoxide. Co-administration of inhibitors of human microsomal epoxide hydrolase may result in increased carbamazepine-10,11 epoxide plasma concentrations.</p><p><strong><em>Interactions resulting in a contraindication</em></strong></p><p>The use of Tegretol is contraindicated in combination with monoamine-oxidase inhibitors (MAOIs); before administering Tegretol MAOIs should be discontinued for a minimum of 2&nbsp;weeks, or longer if the clinical situation permits (see contraindications).</p><p>&nbsp;</p><p><strong><em>Agents that may raise carbamazepine plasma levels:</em></strong></p><p>Since raised plasma carbamazepine levels may result in adverse reactions (e.g. dizziness, drowsiness, ataxia, diplopia), the dosage of Tegretol should be adjusted accordingly and/or the plasma levels monitored when used concomitantly with the substances described below:</p><p><u>Analgesics, anti-inflammatory drugs:</u> dextropropoxyphene.</p><p><u>Androgens</u>: danazol.</p><p><u>Antibiotics:</u> macrolide antibiotics (e.g. erythromycin, clarithromycin), ciprofloxacine.</p><p><u>Antidepressants:</u> fluoxetine, fluvoxamine, paroxetine, trazodone.</p><p><u>Antiepileptics:</u> vigabatrin.</p><p><u>Antifungals:</u> azoles (e.g. itraconazole, ketoconazole, fluconazole, voriconazole). Alternative anti-convulsants may be recommended in patients treated with voriconazole or itraconazole.</p><p><u>Antipsychotics:</u> olanzapine.</p><p><u>Antituberculosis:</u> isoniazid.</p><p><u>Antivirals:</u> protease inhibitors for HIV treatment (e.g. ritonavir).</p><p><u>Carbonic anhydrase inhibitors:</u> acetazolamide.</p><p><u>Cardiovascular drugs:</u> diltiazem, verapamil.</p><p><u>Gastrointestinal drugs:</u> possibly cimetidine, omeprazole.</p><p><u>Other interactions:</u> grapefruit juice, nicotinamide (only in high dosage).</p><p><strong><em>Agents that may raise the active metabolite carbamazepine-10,11-epoxide plasma levels:</em></strong></p><p>Since raised plasma carbamazepine-10,11-epoxide levels may result in adverse reactions (e.g. dizziness, drowsiness, ataxia, diplopia), the dosage of Tegretol should be adjusted accordingly and/or the plasma levels monitored when used concomitantly with the substances described below:</p><p><u>Antiepileptics</u>: Quetiapine, primidone, progabide, valproic acid, valnoctamide ,valpromide&nbsp;and brivaracetam.</p><p>&nbsp;</p><p><strong><em>Agents that may decrease carbamazepine plasma levels:</em></strong>&nbsp;</p><p>The dose of Tegretol may have to be adjusted when used concomitantly with the substances described below:</p><p><u>Antiepileptics:</u> oxcarbazepine, phenobarbital, phenytoin (to avoid phenytoin intoxication and subtherapeutic concentrations of carbamazepine it is recommended to adjust the plasma concentration of phenytoin to 13 micrograms /mL before adding carbamazepine to the treatment) and fosphenytoin, primidone, and, although the data are partly contradictory, possibly also clonazepam.</p><p><u>Antineoplastics:</u> cisplatin or doxorubicin.</p><p><u>Antituberculosis:</u> rifampicin.</p><p><u>Bronchodilatators or anti-asthma drugs:</u> theophylline, aminophylline.</p><p><u>Dermatological drugs:</u> isotretinoin.</p><p><u>Other interactions:</u> herbal preparations containing St John&#39;s wort (Hypericum perforatum).</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Effect of Tegretol on plasma levels of concomitant agents:</em></strong></p><p>Carbamazepine may lower the plasma level, diminish or even abolish the activity of certain drugs.&nbsp; The dosage of the following drugs may have to be adjusted to clinical requirement:</p><p><u>Analgesics, anti-inflammatory agents:</u> buprenorphine, methadone, paracetamol (long term administration of carbamazepine and paracetamol (acetaminophen) may be associated with hepatotoxicity), tramadol.</p><p><u>Antibiotics:</u> doxycycline, rifabutin.</p><p><u>Anticoagulants:</u> oral anticoagulants (e.g. warfarin, acenocoumarol, rivaroxaban, dabigatran, apixaban and edoxaban).</p><p><u>Antidepressants:</u> bupropion, citalopram, mianserin, sertraline, trazodone, tricyclic antidepressants (e.g. imipramine, amitriptyline, nortriptyline, clomipramine).</p><p><u>Antiemetics:</u> aprepitant</p><p><u>Antiepileptics:</u> clobazam, clonazepam, ethosuximide, lamotrigine, eslicarbazepine, oxcarbazepine, primidone, tiagabine, topiramate, valproic acid, zonisamide. To avoid phenytoin intoxication and subtherapeutic concentrations of carbamazepine it is recommended to adjust the plasma concentration of phenytoin to 13 micrograms /mL before adding carbamazepine to the treatment. There have been rare reports of an increase in plasma mephenytoin levels.</p><p><u>Antifungals:</u> itraconazole, voriconazole. Alternative anti-convulsants may be recommended in patients treated with voriconazole or itraconazole.</p><p><u>Antihelmintics:</u> albendazole.</p><p><u>Antineoplastics:</u> imatinib, cyclophosphamide, lapatinib, temsirolimus.</p><p><u>Antipsychotics:</u> clozapine, haloperidol and bromperidol, olanzapine, quetiapine, risperidone, aripiprazole, paliperidone.</p><p><u>Antivirals:</u> protease inhibitors for HIV treatment (e.g. indinavir, ritonavir, saquinavir).</p><p><u>Anxiolytics:</u> alprazolam.</p><p><u>Bronchodilatators or anti-asthma drugs:</u> theophylline.</p><p><u>Contraceptives:</u> hormonal contraceptives (alternative contraceptive methods should be considered).</p><p><u>Cardiovascular drugs:</u> calcium channel blockers (dihydropyridine group) e.g. felodipine, digoxin, simvastatin, atorvastatin, lovastatin, cerivastatin, ivabradine.</p><p><u>Corticosteroids:</u> corticosteroids (e.g. prednisolone, dexamethasone).</p><p><u>Drugs used in erectile dysfunction:</u> tadalafil.</p><p><u>Immunosuppressants:</u> ciclosporin, everolimus, tacrolimus, sirolimus.</p><p><u>Thyroid agents:</u> levothyroxine.</p><p><u>Other drug interactions:</u> products containing oestrogens and/or progesterones.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Combinations that require specific consideration:</em></strong></p><p>Concomitant use of carbamazepine and levetiracetam has been reported to increase carbamazepine-induced toxicity.</p><p>Concomitant use of carbamazepine and isoniazid has been reported to increase isoniazid-induced hepatotoxicity.&nbsp;</p><p>The combination of lithium and carbamazepine may cause enhanced neurotoxicity in spite of lithium plasma concentrations being within the therapeutic range.&nbsp; Combined use of carbamazepine with metoclopramide or major tranquillisers, e.g. haloperidol, thioridazine, may also result in an increase in neurological side-effects.&nbsp;&nbsp;</p><p>Concomitant medication with Tegretol and some diuretics (hydrochlorothiazide, furosemide) may lead to symptomatic hyponatraemia.</p><p>Carbamazepine may antagonise the effects of non-depolarising muscle relaxants (e.g. pancuronium). Their dosage should be raised and patients monitored closely for a more rapid recovery from neuromuscular blockade than expected.&nbsp;</p><p>Carbamazepine, like other psychoactive drugs, may reduce alcohol tolerance.&nbsp; It is therefore advisable for the patient to abstain from alcohol.</p><p>&nbsp;</p><p>Concomitant use of carbamazepine with direct acting oral anti-coagulants (rivaroxaban, dabigatran, apixaban and edoxaban) may lead to reduced plasma concentrations of direct acting oral anti-coagulants, which carries the risk of thrombosis. Therefore, if a concomitant use is necessary, closer monitoring of signs and symptoms of thrombosis is recommended.</p><p>&nbsp;</p><p><strong><em>Interference with serological testing </em></strong></p><p>Carbamazepine may result in false positive perphenazine concentrations in HPLC analysis due to interference.</p><p>&nbsp;</p><p>Carbamazepine and the 10,11-epoxide metabolite may result in false positive tricyclic antidepressant concentration in fluorescence polarized immunoassay method.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>&nbsp;&nbsp; Pregnancy</em></strong></p><p><strong>&nbsp;</strong></p><p><strong>Risk <em>related to antiepileptic medicinal products in general </em></strong></p><p>Specialist medical advice regarding the potential risks to a foetus caused by both seizures and antiepileptic treatment should be given to all women of childbearing potential taking antiepileptic treatment, and especially to women planning pregnancy and women who are pregnant.</p><p>Sudden discontinuation of antiepileptic drug (AED) therapy should be avoided as this may lead to seizures that could have serious consequences for the woman and the unborn child.</p><p>Monotherapy is preferred for treating epilepsy in pregnancy whenever possible because therapy with multiple AEDs could be associated with a higher risk of congenital malformations than monotherapy, depending on the associated AEDs.</p><p>&nbsp;</p><p><strong><em>Risk</em> </strong><strong><em>related to carbamazepine</em></strong></p><p>Carbamazepine crosses the placenta in humans. Epidemiological data from pregnancy registries and cohort studies have shown that children born to mothers with epilepsy treated with carbamazepine during the first trimester of pregnancy are at an increased risk of major congenital malformations. The most common types of major congenital malformations reported in association with carbamazepine include neural tube defects including spina bifida, craniofacial defects including cleft lip/palate, cardiovascular malformations, genitourinary tract defects including hypospadias, skeletal malformations and anomalies involving various body systems. Data derived from a meta-&nbsp;analysis (including registries and cohort studies) has shown that 4.93% of children of epileptic women exposed to carbamazepine monotherapy during first trimester of pregnancy suffer from congenital malformations (95% CI: 3.84-6.16) compared with the background rate on the general population of around 2-3%.&nbsp; Malformations such as neural tube defects (spina bifida), craniofacial defects such as cleft lip/palate, cardiovascular malformations, hypospadias, hypoplasia of the fingers, and other anomalies involving various body systems, have been reported in the offspring of women who used carbamazepine during pregnancy. Specialised antenatal surveillance for these malformations is recommended.</p><p>Neurodevelopmental disorders have been reported among children born to women with epilepsy treated with carbamazepine alone or in combination with other antiepileptic drugs during pregnancy. Studies related to the risk of neurodevelopmental disorders in children exposed to carbamazepine during pregnancy are contradictory and a risk cannot be excluded.</p><p>&nbsp;</p><p>Carbamazepine should not be used during pregnancy unless the benefit is judged to outweigh the risks following careful consideration of alternative suitable treatment options. The woman should be fully informed of and understand the risks of taking carbamazepine during pregnancy.</p><p>Evidence suggest that the risk of malformation with carbamazepine may be dose-dependent, i.e. at a dose &lt; 400mg per day, the rates of malformation were lower than with higher doses of carbamazepine. If based on a careful evaluation of the risks and the benefits, no alternative treatment option is suitable, and treatment with carbamazepine is continued, monotherapy and the lowest effective dose of carbamazepine should be used and monitoring of plasma levels is recommended. The plasma concentration could be maintained in the lower side of the therapeutic range 4 to 12 micrograms/mL provided seizure control is maintained.</p><p>Some antiepileptic drugs, such as carbamazepine, have been reported to decrease serum folate levels. This deficiency may contribute to the&nbsp; increased incidence of birth defects in the offspring of treated epileptic women.</p><p>Folic acid supplementation is recommended before and during pregnancy. In order to prevent bleeding disorders in the offspring, it has also been recommended that vitamin K1 be given to the mother during the last weeks of pregnancy as well as to the neonate.</p><p>If a woman is planning to become pregnant, all efforts should be made to switch to appropriate alternative treatment prior to conception and before contraception is discontinued. If a woman becomes pregnant while taking carbamazepine, she should be referred to a specialist to reassess carbamazepine treatment and consider alternative treatment options.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>In the neonate</em></strong></p><p>There have been a few cases of neonatal seizures and/or respiratory depression associated with maternal Tegretol and other concomitant antiepileptic drug use. A few cases of neonatal vomiting, diarrhoea and/or decreased feeding have also been reported in association with maternal Tegretol use.&nbsp; These reactions may represent a neonatal withdrawal syndrome.</p><p>&nbsp;</p><p>Animal studies have shown reproductive toxicity (see section 5.3).</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Breast-feeding:</em></strong></p><p>&nbsp;</p><p><strong>Risk summary</strong></p><p>Carbamazepine passes into the breast milk <strong>(</strong>about 25-60% of the plasma concentrations).<strong> </strong>&nbsp;The benefits of breast-feeding should be weighed against the remote possibility of adverse effects occurring in the infant.&nbsp; Mothers taking Tegretol may breast-feed their infants, provided the infant is observed for possible adverse reactions (e.g. excessive somnolence, allergic skin reaction). There have been some reports of cholestatic hepatitis in neonates exposed to carbamazepine during antenatal and or during breast feeding. Therefore breast-fed infants of mothers treated with carbamazepine should be carefully observed for adverse hepatobiliary effects.</p><p>&nbsp;</p><p><strong><em>Women of childbearing potential</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Carbamazepine should not be used in women of childbearing potential unless the potential benefit is judged to outweigh the risks following careful consideration of alternative suitable treatment options. The woman should be fully informed of and understand the risk of potential harm to the foetus if carbamazepine is taken during pregnancy and therefore the importance of planning any pregnancy. Pregnancy testing in women of childbearing potential should be considered prior to initiating treatment with carbamazepine.</p><p>Women of childbearing potential should use highly effective contraception during treatment and for at least two weeks after stopping treatment. Due to enzyme induction, carbamazepine may result in a failure of the therapeutic effect of hormonal contraceptives (see section 4.5), therefore, women of childbearing potential should be counselled regarding the use of other effective contraceptive methods. At least one effective method of contraception (such as an intra-uterine device) or two complementary forms of contraception including a barrier method should be used. Individual circumstances should be evaluated in each case, involving the patient in the discussion, when choosing the contraception method.</p><p>&nbsp;</p><p><strong>Contraception</strong></p><p>Due to enzyme induction, Tegretol may result in a failure of the therapeutic effect of oral contraceptive drugs containing oestrogen and/or progesterone.</p><p>Women of childbearing potential should use effective contraception during treatment with Tegretol and for a period of 28 days after discontinuation of treatment. According to national recommendations (FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception), women taking carbamazepine should preferably change to a contraceptive method unaffected by enzyme inducing drugs (i.e. copper IUDs and the levonorgestrel-releasing IUD or depot progestogen-only injections).</p><p>&nbsp;</p><p><strong><em>Fertility:</em></strong></p><p>There have been very rare reports of impaired male fertility and/or abnormal spermatogenesis</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The patient&#39;s ability to react may be impaired by the medical condition resulting in seizures and adverse reactions including dizziness, drowsiness, ataxia, diplopia, impaired accommodation and blurred vision have been reported with Tegretol, especially at the start of treatment or in connection with dose adjustments. Patients should therefore exercise due caution when driving a vehicle or operating machinery.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong></p><p>Particularly at the start of treatment with Tegretol, or if the initial dosage is too high, or when treating elderly patients, certain types of adverse reaction occur very commonly or commonly, e.g. CNS adverse reactions (dizziness, headache, ataxia, drowsiness, fatigue, diplopia); gastrointestinal disturbances (nausea, vomiting), as well as allergic skin reactions.</p><p>The dose-related adverse reactions usually abate within a few days, either spontaneously or after a transient dosage reduction.&nbsp; The occurrence of CNS adverse reactions may be a manifestation of relative overdosage or significant fluctuation in plasma levels.&nbsp; In such cases it is advisable to monitor the plasma levels and divide the daily dosage into smaller (i.e. 3-4) fractional doses.</p><p><strong>Tabulated summary of adverse drug reactions compiled from clinical trials and from spontaneous reports</strong></p><p>Adverse drug reactions from clinical trials are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000).</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Blood and lymphatic system disorders</em></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em>:</p></td><td style="vertical-align:top"><p>leucopenia.</p></td></tr><tr><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>thrombocytopenia, eosinophilia.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:</em></p></td><td style="vertical-align:top"><p>leucocytosis, lymphadenopathy.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Not known:</em></p></td><td style="vertical-align:top"><p>agranulocytosis, aplastic anaemia, pancytopenia, aplasia pure red cell, anaemia, anaemia megaloblastic, reticulocytosis, haemolytic anaemia.&nbsp;</p><p>bone marrow depression.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Immune system disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:&nbsp; </em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Very rare:&nbsp; </em></p><p><em>&nbsp;</em></p><p><em>Not known**:</em></p></td><td style="vertical-align:top"><p>a delayed multi-organ hypersensitivity disorder with fever, rashes, vasculitis, lymphadenopathy, pseudo lymphoma, arthralgia, leucopenia, eosinophilia, hepato-splenomegaly, abnormal liver function tests and vanishing bile duct syndrome (destruction and disappearance of the intrahepatic bile ducts) occurring in various combinations.&nbsp; Other organs may also be affected (e.g. liver<strong>, </strong>lungs, kidneys, pancreas, myocardium, colon).</p><p>anaphylactic reaction, oedema angioedema, hypogammaglobulinaemia.&nbsp;</p><p>Drug Rash with Eosinophilia and Systemic Symptoms (DRESS).</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p><p><em>Not known**:</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>reactivation of Human herpes virus 6 infection.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Endocrine disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em>:&nbsp;</p></td><td style="vertical-align:top"><p>Oedema, fluid retention, weight increase, hyponatraemia and blood osmolarity decreased due to an antidiuretic hormone (ADH)-like effect, leading in rare cases to water intoxication accompanied by lethargy, vomiting, headache, confusional state, neurological disorders.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare: </em></p></td><td style="vertical-align:top"><p>galactorrhoea, gynaecomastia,</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Metabolism and nutrition disorders</em></strong></p><p><em>Rare:</em></p><p><em>Very rare:</em></p><p><em>Not known:</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>folate deficiency, decreased appetite.</p><p>porphyria acute (acute intermittent porphyria and variegate porphyria), porphyria non-acute (porphyria cutanea tarda).</p><p>hyperammonaemia.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Psychiatric</em></strong><em> <strong>disorders</strong></em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:</em></p></td><td style="vertical-align:top"><p>hallucinations (visual or auditory), depression,&nbsp; aggression, agitation, restlessness, confusional state.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:</em></p></td><td style="vertical-align:top"><p>activation of psychosis.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Nervous system disorders</em></strong></p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common:&nbsp; </em></p></td><td style="vertical-align:top"><p>ataxia, dizziness,&nbsp; somnolence.</p></td></tr><tr><td style="vertical-align:top"><p><em>Common:&nbsp; </em></p></td><td style="vertical-align:top"><p>diplopia, headache.</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon: </em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>abnormal involuntary movements (e.g. tremor, asterixis, dystonia, tics), nystagmus.</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:&nbsp; </em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>dyskinesia, eye movementdisorder, speech disorders (e.g. dysarthria or slurred speech), choreoathetosis, neuropathy peripheral, paraesthesia, and paresis.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Not known**:</em></p></td><td style="vertical-align:top"><p>neuroleptic malignant syndrome, aseptic meningitis with myoclonus and peripheral eosinophilia, dysgeusia.</p><p>sedation, memory impairment</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Eye disorders</em></strong></p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Common: </em></p><p><em>Very rare:</em></p></td><td style="vertical-align:top"><p>accommodation disorders (e.g. blurred vision) lenticular opacities, conjunctivitis.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Ear and labyrinth disorders</em></strong></p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:&nbsp; </em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>hearing disorders, e.g. tinnitus, hyperacusis, hypoacusis, change in pitch perception.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Cardiac disorders</em></strong><em> </em></p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:&nbsp; </em></p></td><td style="vertical-align:top"><p>cardiac conduction disorders.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare: </em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>arrhythmia, atrioventricular block with syncope, bradycardia, cardiac failure congestive, coronary artery disease aggravated.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Vascular disorders</em></strong></p><p><em>Rare:</em></p><p><em>Very Rare:</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>hypertension or hypotension.</p><p>circulatory collapse, embolism (e.g. pulmonary embolism), thrombophlebitis.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Respiratory, thoracic and mediastinal disorders</em></strong></p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:&nbsp; </em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>pulmonary hypersensitivity characterised e.g. by fever, dyspnoea, pneumonitis or pneumonia.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Gastro-intestinal disorders</em></strong></p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em>:&nbsp;</p></td><td style="vertical-align:top"><p>vomiting, nausea.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Common:&nbsp; </em></p></td><td style="vertical-align:top"><p>dry mouth, with suppositories rectal irritation may occur.</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:&nbsp; </em></p></td><td style="vertical-align:top"><p>diarrhoea, constipation.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:</em></p></td><td style="vertical-align:top"><p>abdominal pain.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:</em></p><p><em>Not known**:</em></p></td><td style="vertical-align:top"><p>Pancreatitis, glossitis, stomatitis,.&nbsp;</p><p>colitis.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Hepatobiliary disorders</em></strong></p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Rare:&nbsp; </em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>hepatitis of cholestatic, parenchymal (hepatocellular) or mixed type, vanishing bile duct syndrome, jaundice.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:</em></p></td><td style="vertical-align:top"><p>hepatic failure, granulomatous liver disease.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Skin and&nbsp; subcutaneous tissue disorders</em></strong><em>:</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em>:&nbsp;</p></td><td style="vertical-align:top"><p>urticaria, which may be severe dermatitus allergic.</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em>:</p></td><td style="vertical-align:top"><p>dermatitis exfoliative.</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:</em></p></td><td style="vertical-align:top"><p>systemic lupus erythematosus, pruritus.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare</em>:&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Not known**:</em></p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome*, toxic epidermal necrolysis, photosensitivity reaction, erythema multiforme, erythema nodosum, pigmentation disorder, purpura, acne, hyperhydrosis, alopecia, hirsutism.&nbsp;</p><p>Acute Generalized Exanthematous Pustulosis (AGEP)**, &nbsp;lichenoid keratosis, onychomadesis.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Musculoskeletal, connective tissue and bone disorders</em></strong></p><p><em>Rare:</em></p><p><em>Very rare</em>:&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Not known**:</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>muscular weakness.</p><p>bone metabolism disorders (decrease in plasma calcium and blood 25-hydroxy-cholecalciferol) leading to osteomalacia/osteoporosis, arthralgia, myalgia, muscle spasms.&nbsp;</p><p>fracture.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Renal and urinary disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare</em>:&nbsp;</p></td><td style="vertical-align:top"><p>tubulointerstitial nephritis, renal failure, renal impairment (e.g. albuminuria, haematuria, oliguria and blood urea/ azotaemia), urinary retention, urinary frequency,.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Reproductive System</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:</em></p></td><td style="vertical-align:top"><p>sexual disturbances/erecticle dysfunction spermatogenesis abnormal (with decreased sperm count and/or motility).</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>General disorders and administration site conditions</em></strong></p><p><em>Very common:</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>fatigue.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Investigations</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Very common:</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>gamma-glutamyltransferase increased (due to hepatic enzyme induction), usually not clinically relevant.</p></td></tr><tr><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>blood alkaline phosphatase increased.</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>transaminases increased.</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare:</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Not known**:</em></p></td><td style="vertical-align:top"><p>intraocular pressure increased, blood cholesterol increased, high density lipoprotein increased, blood triglycerides increased. Thyroid function test abnormal: decreased L-Thyroxin (free thyroxine, thyroxine, tri-iodothyronine) and increased blood thyroid stimulating hormone, usually without clinical manifestations, blood prolactin increased,</p><p>bone density decreased.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Injury, poisoning and procedural complications</em></strong></p><p><em>Not known**:</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Fall (associated with Tegetol treatment induced ataxia, dizziness, somnolence, hypotension, confusional state, sedation) (see section 4.4 warning and precautions).</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p>* In some Asian countries also reported as rare.&nbsp; See also section 4.4 Special warnings and precautions for use.</p><p>&nbsp;</p><p>**Additional adverse drug reactions from spontaneous reports (frequency not known).</p><p>&nbsp;</p><p>There have been reports of decreased bone mineral density, osteopenia, osteoporosis and fractures in patients on long-term therapy with carbamazepine. The mechanism by which carbamazepine affects bone metabolism has not been identified.</p><p>&nbsp;</p><p>There is increasing evidence regarding the association of genetic markers and the occurrence of cutaneous ADRs such as SJS, TEN, DRESS, AGEP and maculopapular rash. In Japanese and European patients, these reactions have been reported to be associated with the use of carbamazepine and the presence of the HLA-A*3101 allele. Another marker, HLA-B*1502 has been shown to be strongly associated with SJS and TEN among individuals of Han Chinese, Thai and some other Asian ancestry (see sections 4.2 and 4.4 for further information).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>&nbsp;</p><p>o SFDA call center: 19999</p><p>o E-mail: <u>npc.drug@sfda.gov.sa</u></p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To report any complaint(s) : complaints.ksa@novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Signs and symptoms</em></strong></p><p>The presenting signs and symptoms of overdosage involve the central nervous, cardiovascular. respiratory systems and the adverse drug reactions mentioned under section 4.8.&nbsp;</p><p><em>Central nervous system</em>:&nbsp; CNS depression; disorientation, depressed level of consciousness, somnolence, agitation, hallucination, coma; blurred vision, slurred speech, dysarthria, nystagmus, ataxia, dyskinesia, initially hyper-reflexia, later hyporeflexia; convulsions, psychomotor disturbances, myoclonus, hypothermia, mydriasis.&nbsp;</p><p><em>Respiratory system</em>:&nbsp; Respiratory depression, pulmonary oedema.&nbsp;</p><p><em>Cardiovascular system</em>: Tachycardia, hypotension and at times hypertension, conduction disturbance with widening of QRS complex; syncope in association with cardiac arrest.&nbsp;</p><p><em>Gastro-intestinal system</em>: Vomiting, delayed gastric emptying, reduced bowel motility.&nbsp;</p><p><em>Musculoskeletal system: </em>There have been some cases which reported rhabdomyolysis in association with carbamazepine toxicity.</p><p><em>Renal function</em>: Retention of urine, oliguria or anuria; fluid retention, water intoxication due to ADH-like effect of carbamazepine.&nbsp;</p><p><em>Laboratory findings</em>:&nbsp; Hyponatraemia, possibly metabolic acidosis, possibly hyperglycaemia, increased muscle creatine phosphokinase.&nbsp;</p><p>&nbsp;</p><p><strong><em>Management</em></strong></p><p>There is no specific antidote.&nbsp;</p><p>Management should initially be guided by the patient&#39;s clinical condition; admission to hospital.&nbsp; Measurement of the plasma level to confirm carbamazepine poisoning and to ascertain the size of the overdose.&nbsp;</p><p>Evacuation of the stomach, gastric lavage, and administration of activated charcoal.&nbsp; Delay in evacuating the stomach may result in delayed absorption, leading to relapse during recovery from intoxication.<strong>&nbsp; </strong>Supportive medical care in an intensive care unit with cardiac monitoring and careful correction of electrolyte imbalance.&nbsp;</p><p><strong><em>Special recommendations</em></strong>:</p><p>Charcoal haemoperfusion has been recommended. Hemodialysis is the effective treatment modality in the management of the carbamazepine overdose.&nbsp;</p><p>Relapse and aggravation of symptomatology on the 2nd and 3rd day after overdose, due to delayed absorption, should be anticipated.&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapeutic class:&nbsp; Anti-epileptic, neurotropic and psychotropic agent; (ATC Code: N03 AF01).&nbsp; Dibenzazepine derivative.</p><p>As an antiepileptic agent its spectrum of activity embraces: partial seizures (simple and complex) with and without secondary generalisation; generalised tonic-clonic seizures, as well as combinations of these types of seizures.</p><p>The mechanism of action of carbamazepine, the active substance of Tegretol, has only been partially elucidated.&nbsp; Carbamazepine stabilises hyperexcited nerve membranes, inhibits repetitive neuronal discharges, and reduces synaptic propagation of excitatory impulses.&nbsp; It is conceivable that prevention of repetitive firing of sodium-dependent action potentials in depolarised neurons via use- and voltage-dependent blockade of&nbsp; sodium channels may be its main mechanism of action.&nbsp;&nbsp;</p><p>Whereas reduction of glutamate release and stabilisation of neuronal membranes may account for the antiepileptic effects, the depressant effect on dopamine and noradrenaline turnover could be responsible for the antimanic properties of carbamazepine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Absorption</em></p><p>Carbamazepine is almost completely absorbed but the rate of absorption from the tablets is slow and may vary amongst the various formulations and between patients.&nbsp; Peak concentrations of active substance in the plasma are attained within 24 hours of administration of single dose of Tegretol Prolonged Release tablets.</p><p>The prolonged release formulation shows about 15% lower bioavailability than standard preparations due mainly to the considerable reduction in peak plasma levels occasioned by prolonged release of the same dosage of carbamazepine.&nbsp; Plasma concentrations show less fluctuation but auto-induction of carbamazepine occurs as with standard carbamazepine preparations.</p><p>The bioavailability of Tegretol in various oral<strong> </strong>formulations has been shown to lie between 85-100%.<strong> </strong></p><p><strong>&nbsp;</strong></p><p>Ingestion of food has no significant influence on the rate and extent of absorption, regardless of the dosage form of Tegretol.&nbsp;</p><p>&nbsp;</p><p>Steady-state plasma concentrations of carbamazepine are attained within about 1-2 weeks, depending individually upon auto-induction by carbamazepine and hetero-induction by other enzyme-inducing drugs, as well as on pre-treatment status, dosage, and duration of treatment.</p><p>&nbsp;</p><p>Different preparations of carbamazepine may vary in bioavailability; to avoid reduced effect or risk of breakthrough seizures or excessive side effects, it may be prudent to avoid changing the formulation.</p><p>&nbsp;</p><p><em>Distribution</em></p><p>Carbamazepine is bound to serum proteins to the extent of 70-80%.&nbsp; The concentration of unchanged&nbsp; substance in cerebrospinal fluid and saliva reflects the non-protein bound portion in plasma (20-30%).&nbsp; Concentrations in breast milk were found to be equivalent to 25-60% of the corresponding plasma levels.</p><p>&nbsp;</p><p>Carbamazepine crosses the placental barrier.&nbsp; Assuming complete absorption of carbamazepine, the apparent volume of distribution ranges from 0.8 to 1.9 L/kg.&nbsp;</p><p>&nbsp;</p><p><em>Biotransformation</em></p><p>Carbamazepine is metabolised in the liver, where the epoxide pathway of biotransformation is the most important one, yielding the 10, 11-transdiol derivative and its glucuronide as the main metabolites.</p><p>&nbsp;</p><p>Cytochrome P450 3A4 has been identified as the major isoform responsible for the formation of carbamazepine 10, 11-epoxide from carbamazepine. Human microsomal epoxide hydrolase has been identified as the enzyme responsible for the formation of the 10,11-transdiol derivative from carbamazepine-10,11 epoxide. 9-Hydroxy-methyl-10-carbamoyl acridan is a minor metabolite related to this pathway.&nbsp; After a single oral dose of carbamazepine about 30% appears in the urine as end-products of the epoxide pathway.</p><p>&nbsp;</p><p>Other important biotransformation pathways for carbamazepine lead to various monohydroxylated compounds, as well as to the N-glucuronide of carbamazepine&nbsp; produced by UGT2B7.</p><p>&nbsp;</p><p><em>Elimination</em></p><p>The elimination half-life of unchanged carbamazepine averages approx. 36 hours following a single oral dose, whereas after repeated administration it averages only 16-24 hours (auto-induction of the hepatic mono-oxygenase system), depending on the duration of the medication.&nbsp; In patients receiving concomitant treatment with other enzyme-inducing drugs (e.g. phenytoin, phenobarbitone),&nbsp; half-life values averaging 9-10 hours have been found.</p><p>&nbsp;</p><p>The mean elimination half-life of the 10, 11-epoxide metabolite in the plasma is about 6 hours following single oral doses of the epoxide itself.&nbsp;</p><p>&nbsp;</p><p>After administration of a single oral dose of 400mg carbamazepine, 72% is excreted in the urine and 28% in the faeces.&nbsp; In the urine, about 2% of the dose is recovered as unchanged drug and about 1% as the pharmacologically active 10, 11-epoxide metabolite.&nbsp;</p><p>&nbsp;</p><p><em>Characteristics in patients</em></p><p>The steady-state plasma concentrations of carbamazepine considered as &ldquo;therapeutic range&rdquo; vary considerably inter-individually; for the majority of patients a range between 4-12&micro;g/ml corresponding to 17-50&micro;mol/l has been reported.&nbsp; Concentrations of carbamazepine 10, 11-epoxide (pharmacologically active metabolite):&nbsp; about 30% of carbamazepine levels.</p><p>&nbsp;</p><p><strong>Special populations</strong></p><p><em>&nbsp;</em></p><p><em>Paediatric populations&nbsp;(below 18 years)</em></p><p>Owing to enhanced carbamazepine elimination, children may require higher doses of carbamazepine (in mg/kg) than adults to maintain therapeutic concentrations.</p><p>&nbsp;</p><p><em>Elderly population (65 years or above)</em></p><p>There is no indication of altered pharmacokinetics of carbamazepine in elderly patients as compared with young adults.</p><p>&nbsp;</p><p><em>&nbsp;hepatic or renal impairment</em></p><p>No data are available on the pharmacokinetics of carbamazepine in patients with impaired hepatic or renal function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity, local tolerance, genotoxicity and carcinogenic potential. Reproductive toxicity studies in animals were insufficient to rule out a teratogenic effect of carbamazepine in humans.</p><p><strong>&nbsp;</strong></p><p><strong>Carcinogenicity</strong></p><p>In rats treated with carbamazepine for two years, there was an increased incidence of hepatocellular tumours in females and benign testicular tumours in males. However, there is no evidence to date that these observations are of any relevance to the therapeutic use of carbamazepine in humans.</p><p><strong>&nbsp;</strong></p><p><strong>Reproductive toxicity</strong></p><p>&nbsp;</p><p><strong>Animal data</strong></p><p>The cumulative evidence from various animal studies in mice, rats and rabits indicates that carbamazepine has no or only minor teratogenic potential at doses relevant to man. However, the animal studies were insufficient to rule out a teratogenic effect of carbamazepine.</p><p>&nbsp;</p><p>Published studies indicate that carbamazepine is a teratogen in rats and mice (craniofacial and limb malformations) with the effects in mice reported at clinically relevant doses.</p><p>Intrauterine growth restrictions (e.g reduced crown-rump lengths), delayed skeletal ossification and reduced fetal weights have been reported in multiple studies in rodents in the open literature.</p><p>&nbsp;</p><p>In a reproduction study in rats, nursing offspring demonstrated a reduced weight gain at a maternal dosage level of 192 mg/kg/day.</p><p>&nbsp;</p><p>There are some reports of neurodegenerative changes in the brains of offspring exposed to carbamazepine during pregnancy from rodent studies published in the open literature. However, limitations in the study design means the toxicological significance and clinical relevance of these findings are unclear.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>In chronic toxicity studies dose related testicular atrophy and aspermatogenesis occurred in rats receiving carbamazepine. The safety margin for this effect is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each tablet contains colloidal silicon dioxide, ethylcellulose aqueous dispersion (30%), microcrystalline cellulose, ethyl acrylate/methyl methacrylate copolymer, magnesium stearate, croscarmellose sodium type A, talc, hydroxypropylmethylcellulose, glyceryl polyoxyethylene glycol stearate, red iron oxide (E.172), yellow iron oxide (E.172) and titanium dioxide (E.171).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Do not store above 30&deg;C.</li><li>Store in the original package in order to protect from moisture.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Tegretol Prolonged Release Tablets 200mg come in PVC/PE/PVdC blister packs of 50 tablets.&nbsp;</li><li>Tegretol Prolonged Release Tablets 400mg come in PVC/PE/PVdC blister packs of 30 tablets.&nbsp;</li><li>&nbsp;&nbsp; Not all pack sizes may be marketed.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Handling:</u></p><p>Tegretol is an anti-epileptic medical product. In healthcare settings, use designated area for medication storage and restrict access to only authorized personnel.</p><p>&nbsp;</p><p><u>Disposal:</u></p><p>Any unused medicinal product or waste material should be disposed in accordance with local requirements. Wash hands thoroughly with water after disposal of any unused medicinal product or waste material. For further instructions on handling and disposal of this medicine, please refer to local guidelines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>